

*Classified p.a.*

*W0 97/39740*

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptal626amd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and  
IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and  
ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on  
STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available

NEWS 39 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
 NEWS 40 Jan 21 PHARMAML offering one free connect hour in February 2003  
 NEWS 41 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
 ENERGY, INSPEC  
 NEWS 42 Feb 13 CANCERLIT is no longer being updated  
 NEWS 43 Feb 24 METADEX enhancements  
 NEWS 44 Feb 24 PCTGEN now available on STN  
 NEWS 45 Feb 24 TEMA now available on STN  
 NEWS 46 Feb 26 NTIS now allows simultaneous left and right truncation  
 NEWS 47 Feb 26 PCTFULL now contains images  
 NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
 NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003  
 NEWS 50 Mar 20 EVENTLINE will be removed from STN  
 NEWS 51 Mar 24 PATDPAFULL now available on STN  
 NEWS 52 Mar 24 Additional information for trade-named substances without  
 structures available in REGISTRY  
 NEWS 53 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
 CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS INTER General Internet Information  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:11:52 ON 01 APR 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:11:57 ON 01 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAR 2003 HIGHEST RN 501072-24-8  
 DICTIONARY FILE UPDATES: 31 MAR 2003 HIGHEST RN 501072-24-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09926739.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 13:12:14 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

<-----User Break----->

< 0.8% PROCESSED 43453 ITERATIONS

1 ANSWERS

SEARCH ENDED BY USER

SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*

BATCH \*\*INCOMPLETE\*\*

PROJECTED ITERATIONS: EXCEEDS 1000000

PROJECTED ANSWERS: EXCEEDS 86

L2 1 SEA SSS FUL L1

=>


Uploading 09926739.str

L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 13 ful

FULL SEARCH INITIATED 13:13:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 85161 TO ITERATE

100.0% PROCESSED 85161 ITERATIONS

324 ANSWERS

SEARCH TIME: 00.00.03

L4 324 SEA SSS FUL L3

=> s 14 and caplus/lc

27067097 CAPLUS/LC


L5 317 L4 AND CAPLUS/LC

=> s 14 not 15

L6 7 L4 NOT L5


=> d 1-7

L6 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 227808-81-3 REGISTRY  
 CN 3-Pyrrolidinamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-ethyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C25 H32 N2 O S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 179616-74-1 REGISTRY  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-3-methyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C17 H25 N O2 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 142934-92-7 REGISTRY  
 CN Benzo[b]thiophene-6-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C16 H23 N O2 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 142934-90-5 REGISTRY  
 CN Benzo[b]thiophene-4-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C16 H23 N O2 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 131965-18-9 REGISTRY  
 CN Ethanaminium,  
 2-(2-benzo[b]thien-5-yl-2-hydroxyethoxy)-N,N,N-trimethyl-  
 (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C15 H22 N O2 S  
 CI COM  
 SR CA




L6 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 131964-67-5 REGISTRY  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-[methyl(phenylmethyl)amino]ethox  
 ylmethyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C20 H23 N O2 S  
 CI COM  
 SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 131964-53-9 REGISTRY  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(dimethylamino)propoxy]methyl]-  
 (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C15 H21 N O2 S  
 CI COM  
 SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

312.68

312.89

FILE 'CAPLUS' ENTERED AT 13:13:36 ON 01 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Apr 2003 VOL 138 ISS 14

FILE LAST UPDATED: 31 Mar 2003 (20030331/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:11:52 ON 01 APR 2003)

FILE 'REGISTRY' ENTERED AT 13:11:57 ON 01 APR 2003

L1 STRUCTURE UPLOADED

L2 1 S L1 FUL

L3 STRUCTURE UPLOADED

L4 324 S L3 FUL

L5 317 S L4 AND CAPLUS/LC

L6 7 S L4 NOT L5

FILE 'CAPLUS' ENTERED AT 13:13:36 ON 01 APR 2003

=> s l4


L7 37 L4

=> d 1-37 ibib abs hitstr

L7 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2003:112901 CAPLUS  
DOCUMENT NUMBER: 138:142512  
TITLE: Ethanediol derivatives for inhibiting cerebral infarction  
INVENTOR(S): Kurimoto, Hiroaki; Ono, Tetsu  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JKKXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003040772	A2	20030213	JP 2002-145681	20020521
PRIORITY APPLN. INFO.:			JP 2001-153650	A 20010523
OTHER SOURCE(S):			MARPAT 138:142512	
AB			1,2-Ethanediol deriva., R1CH(OR2)CHR3O(CR4R5)nR6 [R1 = (substituted) heterocyclic ring; R2 = H or OH-protecting group; R3 = H, lower alkyl; R4, R5 = H, lower alkyl; R6 = (substituted) amino, ammonio group; n = 1-6] or salts thereof, inhibit the progress of ischemia-induced cerebral infarction. Oral administration of T-588 to cerebral artery-obstructed rat models showed that the T-588 was effective in decreasing the size of obstructed area. Tablets contg. T-588 50 mg/each were formulated.	
IT			142935-03-3, T 588 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ethanediol derivs. for inhibiting cerebral infarction)	
RN			142935-03-3 CAPLUS	
CN			Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



● HCl

L7 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl

L7 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:900735 CAPLUS  
DOCUMENT NUMBER: 137:363121  
TITLE: Remedy for impendent urinary incontinence containing  
INVENTOR(S): 1,2-ethanediol derivative or its salt  
Nakata, Yasushi; Ono, Satoshi  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
CODEN: JKKXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002338465	A2	20021127	JP 2002-64693	20020311
PRIORITY APPLN. INFO.:			JP 2001-68057	A 20010312
OTHER SOURCE(S):			MARPAT 137:363121	
AB			Remedy for impendent urinary incontinence accompanied by various diseases due to the obstacle or denaturation of central nervous system was offered.	
			1,2-Ethanediol deriv. or its salt represented by the following general formula 1, (R1CH(OR2)CH(R3)O(C(R4)(R5))nR6 where R1 = (substituted) heterocyclic ring; R2 = H or OH protective group; R3 = H or low alkyl; n = 1-6; R4, R5 = same or different H or low alkyl; R6 = (substituted) amino or ammonio) is used in the treatment of overactive bladder activity induced by cerebral infarction and pollakiuria and the nighttime pollakiuria (chief complaint of impendent urinary incontinence) accompanied by various diseases due to the obstacle or denaturation of central nervous system such as cerebrovascular disorder, Parkinson's disease and various neuropathy.	
IT			142935-03-3, T-588 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (remedy for impendent urinary incontinence contg. 1,2-ethanediol derivs. or its salt)	
RN			142935-03-3 CAPLUS	
CN			Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.

L7 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:847700 CAPLUS  
DOCUMENT NUMBER: 137:329485  
TITLE: Ethanediol derivatives for the restoration of mitochondria functions  
INVENTOR(S): Baba, Akinichi; Matsuda, Toshio  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
CODEN: JKKXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002322058	A2	20021108	JP 2001-360376	20011127
PRIORITY APPLN. INFO.:			JP 2001-102082	A 20010226
AB			This invention relates to the use of ethanediol derivs., esp. T-588, for the activation of mitochondrial functions, thereby for treating neurodegenerative diseases, circulatory system diseases, vision disorders, etc. In vitro expts. showed that T-588 at 100 .mu.mol/L increased MTT redn. capability in astrocytes by 1.6 times. Tablets and capsules contg. 50 mg T-588 each, were formulated.	
IT			142935-03-3, T-588 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ethanediol derivs. for restoration of mitochondria functions)	
RN			142935-03-3 CAPLUS	
CN			Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



● HCl




L7 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:769642 CAPLUS  
DOCUMENT NUMBER: 137:273223  
TITLE: Brain-derived neurotrophic factor  
activity-enhancing  
agents containing 1,2-ethanediol derivatives  
INVENTOR(S): Ukai, Wataru; Ono, Tetsu  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
CODEN: JKKXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002293741	A2	20021009	JP 2002-14935	20020124
PRIORITY APPLN. INFO.:			JP 2001-16464	A 20010125

OTHER SOURCE(S): MARPAT 137:273223  
AB The invention provides 1,2-ethanediol derivs.  
R1C(OR2)HC(R3)HO(R4)(R5)CnR6 (R1 = heterocyclic group; R2 = H,  
hydroxyl-protecting group; R3, R4, R5 = H, lower alkyl; R6 = amino,  
ammonio; n = 1-6) having brain-derived neurotrophic factor (BDNF)  
activity-enhancing effect. Pharmaceutical compns. contg. the  
1,2-ethanediol derivs. and BDNF are also disclosed. The inhibitory  
effect of T-588 on amyloid .beta.-induced cerebral nerve injury in rats was  
examd. A tablet contg. T-588 50 mg was formulated.  
IT 142935-03-3, T-588  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(brain-derived neurotrophic factor activity-enhancing agents  
contg. 1,2-ethanediol derivs.)  
RN 142935-03-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
hydrochloride, (.alpha.)R- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of benzothienylalkoxyalkylamines having antihypoxia,  
nerve-protecting, and nerve-regenerating activity)  
RN 313061-21-1 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-ylethoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 448218-76-6 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 448220-85-7 CAPLUS  
CN Ethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-(methylsulfinyl)-  
(9CI) (CA INDEX NAME)



RN 448221-02-1 CAPLUS  
CN 1,2-Ethanediolamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N'-methyl-  
(9CI) (CA INDEX NAME)




IT 313061-16-4P, N-[2-(2-(Benzothienophen-5-yl)ethoxy)ethyl]-N-(2-propionyl)amine 313061-18-6P, 1-[[2-(2-(Benzothienophen-5-yl)ethoxy)ethyl]amino]-2-propanol 313061-19-7P, 3-[[2-(2-(Benzothienophen-5-yl)ethoxy)ethyl]amino]-1-propanol 313061-20-0P, 2-[[2-(2-(Benzothienophen-5-yl)ethoxy)ethyl]amino]-1-

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:636475 CAPLUS  
DOCUMENT NUMBER: 137:169412  
TITLE: Preparation of N-benzothienylalkoxyalkyl-N-alkylamines and their salts having antihypoxia, nerve-protecting, and nerve-regenerating activity  
INVENTOR(S): Saito, Akito; Takamatsu, Tamotsu  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.  
CODEN: JKKXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002234865	A2	20020823	JP 2001-373563	20011207
PRIORITY APPLN. INFO.:			JP 2000-373623	A 20001208

OTHER SOURCE(S): MARPAT 137:169412




AB The compds. I (R1 = H, halo, alkyl, aryl, aralkyl, NO2, oxo, etc.; R2 = H, halo, alkyl, aryl, aralkyl, NO2; R3 = lower alkyl, cycloalkyl, lower alkoxy, aryloxy, lower alkylthio, etc.; R4-R7 = H, lower alkyl; D ring 5- or 6-membered hydrocarbon ring; m = 2-6; n = 1-6) or their salts are prepd. 2-[2-(1-Benzothiophen-5-yl)ethoxy]-N-methylacetamide (2.0 g) was treated with borane-THF complex in THF at room temp. for 13 h to give 1.35 g N-[2-[2-(1-benzothiophen-5-yl)ethoxy]ethyl]-N-methylamine, which was reacted with HCl in AcOEt at room temp. to 5.degree. for 2 h to give 1.15 g N-[2-[2-(1-benzothiophen-5-yl)ethoxy]ethyl]-N-methylamine hydrochloride showing antihypoxia activity at 100 mg/kg in mice.  
IT 313061-21-1P, N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-methylamine 448218-76-6P, 2-[[2-(2-(Benzothiophen-5-yl)ethoxy)ethyl]amino]-1-ethanol 448220-85-7P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-[2-(methylsulfinyl)ethyl]-1-ethanamine 448221-02-1P, N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-[2-(methylamino)ethyl]amine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
propanol 313061-22-2P, N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-(2-methoxyethyl)amine 448218-75-5P, N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-propylamine 448218-78-0P,  
N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-[2-(dimethylamino)ethyl]amine 448218-80-2P, 3-[[2-(2-(Benzothiophen-5-yl)ethoxy)ethyl]amino]-1,2-propanediol 448218-81-3P, 2-[[2-(2-(Benzothiophen-5-yl)ethoxy)ethyl]amino]cyclohexanol 448218-83-5P, 2-[[2-(2-(Benzothiophen-5-yl)ethoxy)ethyl]amino]-1-ethanethiol 448218-84-6P, 2-[2-[2-(6-Fluoro-benzothiophen-5-yl)ethoxy]ethyl]amino]-1-ethanol 448218-85-7P, 2-[[2-[3-(Benzothiophen-5-yl)propoxy]ethyl]amino]-1-ethanol 448218-87-9P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-2-methyl-1-propanol 448218-90-4P 448218-92-6P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]-1-methylethyl]amino]-1-ethanol 448218-98-2P, N-(2-Aminoethyl)-N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amine 448219-01-0P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-1,3-propanediol 448219-14-5P, 2-[[3-[2-(Benzothiophen-5-yl)ethoxy]propyl]amino]-1-ethanol 448219-31-6P, 2-[[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-[2-(methylsulfinyl)ethyl]-1-ethanamine 448219-36-1P 448219-42-9P 448219-51-0P 448219-57-6P,


N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-[2-(dimethylamino)ethyl]amine dihydrochloride 448219-64-5P, 3-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-1,2-propanediol hydrochloride 448219-72-5P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]cyclohexanol hydrochloride 448219-85-0P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-1-ethanethiol hydrochloride 448219-93-0P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-2-methyl-1-propanol hydrochloride 448220-01-7P 448220-08-4P, 1-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-2-propanol hydrochloride 448220-18-6P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]-1-methylethyl]amino]-1-ethanol hydrochloride 448220-23-3P, N-(2-Aminoethyl)-N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amine dihydrochloride 448220-27-7P, 2-[[3-[2-(Benzothiophen-5-yl)ethoxy]propyl]amino]-1-ethanol hydrochloride 448220-31-3P,

2-[2-(Benzothiophen-5-yl)ethoxy]-N-[2-(methylsulfinyl)ethyl]-1-ethanamine hydrochloride 448220-35-7P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-1-ethanol oxalate 448220-42-6P, N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-(2-methoxyethyl)amine oxalate 448220-46-0P, 2-[[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amino]-1-propanol oxalate 448220-51-7P, 2-[[2-[2-(6-Fluoro-benzothiophen-5-yl)ethoxy]ethyl]amino]-1-ethanol oxalate 448220-55-1P, 2-[[2-[3-(Benzothiophen-5-yl)propoxy]ethyl]amino]-1-ethanol oxalate 448220-67-5P 448221-07-6P, N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]-N-[3-(methylamino)propyl]amine 448221-11-2P, N-(3-Aminopropyl)-N-[2-[2-(Benzothiophen-5-yl)ethoxy]ethyl]amine 448221-19-0P, 3-[[3-[2-(Benzothiophen-5-yl)ethoxy]propyl]amino]-1,2-propanediol 448221-23-6P, 2-[2-[2-(Benzothiophen-5-yl)ethoxy]-N-[2-(methylsulfinyl)ethyl]-1-ethanamine hydrochloride 448221-32-7P, 3-[[3-[2-(Benzothiophen-5-yl)ethoxy]propyl]amino]-1,2-propanediol hydrochloride 448221-36-1P, N-[2-[2-(Benzothiophen-5-


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 yl)ethoxy]ethyl]-N-[2-(methylamino)ethyl]amine dihydrochloride  
**448221-41-8P**, N-[2-[2-(Benzo[thiophen-5-yl]ethoxy)ethyl]-N-[3-(methylamino)propyl]amine dihydrochloride **448221-45-2P**,  
 N-(3-Aminopropyl)-N-[2-[2-(benzo[thiophen-5-yl]ethoxy)ethyl]amine dihydrochloride **448222-27-3P**, N-[2-[2-(Benzo[thiophen-5-yl]ethoxy)ethyl]-N-butylamine  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of benzo[thiophenyl]alkoxyalkylamines having antihypoxia, nerve-protecting, and nerve-regenerating activity)  
 RN 313061-16-4 CAPLUS  
 CN 2-Propyn-1-amine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 313061-18-6 CAPLUS  
 CN 2-Propanol, 1-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 313061-19-7 CAPLUS  
 CN 1-Propanol, 3-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 313061-20-0 CAPLUS  
 CN 1-Propanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 448218-81-3 CAPLUS  
 CN Cyclohexanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 448218-83-5 CAPLUS  
 CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 448218-84-6 CAPLUS  
 CN Ethanol, 2-[[2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 448218-85-7 CAPLUS  
 CN Ethanol, 2-[[2-(3-benzo[b]thien-5-ylpropoxy)ethyl]amino]- (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313061-22-2 CAPLUS  
 CN Ethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 448218-75-5 CAPLUS  
 CN 1-Propanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 448218-78-8 CAPLUS  
 CN 1,2-Ethanediamine, N'-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 448218-80-2 CAPLUS  
 CN 1,2-Propanediol, 3-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 448218-87-9 CAPLUS  
 CN 1-Propanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 448218-90-4 CAPLUS  
 CN Cyclopropanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 448218-92-6 CAPLUS  
 CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)-1-methylethyl]amino]- (9CI) (CA INDEX NAME)




RN 448218-98-2 CAPLUS  
 CN 1,2-Ethanediamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 448219-01-0 CAPLUS  
CN 1,3-Propanediol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-  
(9CI) (CA INDEX NAME)




RN 448219-14-5 CAPLUS  
CN Ethanol, 2-[[3-(2-benzo[b]thien-5-ylethoxy)propyl]amino]- (9CI) (CA INDEX NAME)



RN 448219-31-6 CAPLUS  
CN Ethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-(methylthio)-  
(9CI) (CA INDEX NAME)




RN 448219-36-1 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-ylethoxy)-N-methyl-, hydrochloride  
(9CI) (CA INDEX NAME)



● HCl


RN 448219-42-9 CAPLUS

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 448219-72-5 CAPLUS  
CN Cyclohexanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 448219-85-0 CAPLUS  
CN Ethanethiol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 448219-93-0 CAPLUS  
CN 1-Propanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-2-methyl-,  
hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN 1-Propanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-, hydrochloride  
(9CI) (CA INDEX NAME)




● HCl

RN 448219-51-0 CAPLUS  
CN 1-Butanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-, hydrochloride  
(9CI) (CA INDEX NAME)



● HCl


RN 448219-57-6 CAPLUS  
CN 1,2-Ethanediolamine, N'-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N,N-dimethyl-,  
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 448219-64-5 CAPLUS  
CN 1,2-Propanediol, 3-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-,  
hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 448220-01-7 CAPLUS  
CN Cyclopropanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 448220-08-4 CAPLUS  
CN 2-Propanol, 1-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 448220-18-6 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)-1-methylethyl]amino]-,  
hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 448220-23-3 CAPLUS  
CN 1,2-Ethanediamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 448220-27-7 CAPLUS  
CN Ethanol, 2-[[3-(2-benzo[b]thien-5-ylethoxy)propyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 448220-31-3 CAPLUS  
CN Ethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-(methylthio)-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl


RN 448220-35-7 CAPLUS  
CN Ethanedioic acid, mono[2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]ethyl] ester (9CI) (CA INDEX NAME)



RN 448220-42-6 CAPLUS  
CN Ethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-methoxy-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313061-22-2  
CMF C15 H21 N O2 S




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 448220-46-0 CAPLUS  
CN Ethanedioic acid, mono[2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]propyl] ester (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 448220-51-7 CAPLUS  
CN Ethanedioic acid, mono[2-[[2-(2-(6-fluorobenzo[b]thien-5-yl)ethoxy)ethyl]amino]ethyl] ester (9CI) (CA INDEX NAME)




RN 448220-55-1 CAPLUS  
CN Ethanedioic acid, mono[2-[[2-(3-benzo[b]thien-5-ylpropoxy)ethyl]amino]ethyl] ester (9CI) (CA INDEX NAME)



RN 448220-67-5 CAPLUS  
CN 1,3-Propanediol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 448219-01-0  
CMF C15 H21 N O3 S




CM 2

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


CRN 144-62-7  
CMF C2 H2 O4




RN 448221-07-6 CAPLUS  
CN 1,3-Propanediamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 448221-11-2 CAPLUS  
CN 1,3-Propanediamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 448221-19-0 CAPLUS  
CN 1,2-Propanediol, 3-[[3-(2-benzo[b]thien-5-ylethoxy)propyl]amino]- (9CI) (CA INDEX NAME)




RN 448221-23-6 CAPLUS  
CN Ethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-(methylsulfinyl)-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 2 HCl

RN 448221-32-7 CAPLUS  
CN 1,2-Propanediol, 3-[[3-(2-benzo[b]thien-5-ylethoxy)propyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 448221-36-1 CAPLUS  
CN 1,2-Ethanediamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N'-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 448221-41-8 CAPLUS  
CN 1,3-Propanediamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N'-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 448218-86-8 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 448219-25-8 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)




RN 448221-15-6 CAPLUS  
CN Propanamide, 3-(2-benzo[b]thien-5-ylethoxy)-N-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)




IT 448218-74-4P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-methylacetamide  
448221-52-1P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-propylacetamide  
448221-56-5P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-butylacetamide  
448221-60-1P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-(2-hydroxyethyl)acetamide 448221-68-9P, 2-[2-(Benzothiophen-5-

L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 2 HCl

RN 448221-45-2 CAPLUS  
CN 1,3-Propanediamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 448222-27-3 CAPLUS  
CN 1-Butanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (9CI) (CA INDEX NAME)




IT 448218-79-9, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-(2,3-dihydroxypropyl)acetamide 448218-86-8, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-(2-hydroxy-1,1-dimethylethyl)acetamide 448219-25-8, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-(2-(methylsulfanyl)ethyl)acetamide 448221-15-6, 3-[2-(Benzothiophen-5-yl)ethoxy]-N-(2,3-dihydroxypropyl)propanamide  
RL: RCT (Reactant); RACT (Reactant or reagent) (prepn. of benzothiophenylalkoxyalkylamineshaving antihypoxia, nerve-protecting, and nerve-regenerating activity)  
RN 448218-79-9 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

yl)ethoxy]-N-(2-methoxyethyl)acetamide 448221-72-5P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-[2-(dimethylamino)ethyl]acetamide 448221-76-9P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-(2-hydroxy-1-methylethyl)acetamide 448221-83-8P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-[2-hydroxycyclohexyl]acetamide 448221-91-8P, 2-[2-(Benzothiophen-5-yl)ethoxy]-N-(2-sulfanylethyl)acetamide 448221-95-2P, 2-[2-(6-Fluoro-benzothiophen-5-yl)ethoxy]-N-(2-hydroxyethyl)acetamide 448222-00-2P, 2-[3-(Benzothiophen-5-yl)propoxy]-N-(2-hydroxyethyl)acetamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT (Reactant or reagent) (prepn. of benzothiophenylalkoxyalkylamineshaving antihypoxia, nerve-protecting, and nerve-regenerating activity)  
RN 448218-74-4 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 448221-52-1 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-propyl- (9CI) (CA INDEX NAME)




RN 448221-56-5 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-butyl- (9CI) (CA INDEX NAME)




RN 448221-60-1 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
INDEX NAME)




RN 448221-68-9 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-methoxyethyl)- (9CI)  
(CA INDEX NAME)



RN 448221-72-5 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-(dimethylamino)ethyl)- (9CI) (CA INDEX NAME)



RN 448221-76-9 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 448221-83-8 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-hydroxycyclohexyl)- (9CI)  
(CA INDEX NAME)

L7 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2002:636459 CAPLUS  
DOCUMENT NUMBER: 137:150262  
TITLE: 1,2-Ethanediol derivatives as neurotrophin-like substances for treatment of nerve degenerative diseases  
INVENTOR(S): Ono, Tetsu  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JXXXXF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002234841	A2	20020823	JP 2001-368329	20011203


PRIORITY APPLN. INFO.: JP 2000-371268 A 20001206  
OTHER SOURCE(S): MARPAT 137:150262  
AB 1,2-Ethanediol derivs. (R1CH(OR2)CH(R3)O[C(R4)(R5)]nR6, (I); R1 = (substituted)heterocyclic; R2 = H, OH; R3 = H, low alkyl; n = 1-6; R4, R5 = H, low alkyl; R6 = (substituted)amino, ammonio, e.g. 1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol, and their salts and optical isomers are claimed as neurotrophin-like substances for treatment of nerve degenerative diseases, including Alzheimer's disease, senile dementia, Parkinson disease, diabetic neuropathy, etc.  
Formulation examples of 1 tablets and capsules were given.  
IT 142935-03-3, T 588 392233-09-9D, Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, (.alpha.R)-, (.alpha.R)-, and isomers  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(1,2-ethanediol derivs. as neurotrophin-like substances for treatment of nerve degenerative diseases)  
RN 142935-03-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 448221-91-8 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-mercaptoethyl)- (9CI)  
(CA INDEX NAME)




RN 448221-95-2 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-yl)ethoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 448222-00-2 CAPLUS  
CN Acetamide, 2-(3-benzo[b]thien-5-ylpropoxy)-N-(2-hydroxyethyl)- (9CI)  
(CA INDEX NAME)




L7 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl

RN 392233-09-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:293441 CAPLUS  
DOCUMENT NUMBER: 136:319410  
TITLE: Remedies for retinal nerve diseases containing  
1,2-ethanediol derivatives or salts thereof  
INVENTOR(S): Ono, Satoshi  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 17 pp.  
CODEN: PIXKD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030420	A1	20020418	WO 2001-3P8745	20011004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2001092351 A5 20020422 AU 2001-92351 20011004 PRIORITY APPLN. INFO.: JP 2000-308721 A 20001010 WO 2001-JP8745 W 20011004				

OTHER SOURCE(S): MARPAT 136:319410  
AB 1,2-Ethanediol derivs. represented by the following general formula  
R1CH(OR2)CH(R3)O[C(R4)(R5)]nR6 or salts thereof wherein R1  
represents an optionally substituted heterocyclic group; R2 represents hydrogen or a hydroxyl-protective group; R3 represents hydrogen or lower alkyl; n  
R4s and R5s may be either the same or different and each represents hydrogen or lower alkyl; R6 represents optionally substituted amino or ammonio; and  
n is an integer of from 1 to 6; show a retinal nerve cell protecting effect in a glaucoma model and a rat retinal ischemia recanalization model. They inhibit retinal nerve cell death and, therefore, are useful as preventives and remedies for retinal nerve diseases such as glaucoma, diabetic retinopathy, retinal artery occlusion, retinal vein occlusion, macular degeneration and retinopathy of prematurity.

L7 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:284118 CAPLUS  
DOCUMENT NUMBER: 137:179738  
TITLE: T-588 enhances neurite outgrowth and choline acetyltransferase in cultured rat spinal ventral horn neurons  
AUTHOR(S): Iwasaki, Yasuo; Ikeda, Ken; Ichikawa, Yasumitsu; Igarashi, Osamu; Kinoshita, Masao; Marubuchi, Shigeki  
CORPORATE SOURCE: Ono, Satoshi  
Fourth Department of Internal Medicine, Toho University Ohashi Hospital, Tokyo, 153-8515, Japan  
SOURCE: Neurochemical Research (2002), 27(3), 225-228  
CODEN: NERE2D; ISSN: 0364-3190  
PUBLISHER: Kluwer Academic/Plenum Publishers  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB T-588  
[R(-)-1-(benzo(b)thiophen-5yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride] is a novel compd. which has been shown to exhibit a wide

range of neurotrophic effects both in vivo and in vitro. This compd. can slow the motor deterioration of wobbler mouse motor neuron disease. However, it is not known whether this compd. has a trophic effect on spinal motor neurons. We have studied the effect of T-588 on neurite outgrowth and choline acetyltransferase (ChAT) activity in primary explant cultures of ventral spinal cord of fetal rats (VSCC). Cultures were treated with T-588 from day 1 to 1 wk. T-588 treated VSCC, compared with control VSCC, had a significant neurite promoting effect at ranged between 10-8 molar (M) and 10-5 M, with 2.3 to 5.3 fold increased over that of control at 10-6, and 10-5 M resp. Our data showing T-588 has neurotrophic action on VSCC and suggests a potential use of T-588 in treating diseases that involve degeneration and death of spinal motor neurons, such as motor neuropathy and motor neuron disease.


IT 142935-03-3, T-588  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(T-588 enhances neurite outgrowth and choline acetyltransferase in cultured rat spinal ventral horn neurons)  
RN 142935-03-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
IT 142935-03-3, T-588  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(remedies for retinal nerve diseases contg. 1,2-ethanediol derivs.

or salts thereof)  
RN 142935-03-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl


REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:77415 CAPLUS  
 DOCUMENT NUMBER: 136:139831  
 TITLE: Transdermal compositions containing  
 1,2-ethanediol  
 derivatives  
 INVENTOR(S): Hori, Mitsuhiro; Matsuoka, Kensuke; Ajinomi,  
 Kenjiro  
 Nakano, Yoshihisa; Moriyama, Junichi; Yamakawa,  
 Tetsunori; Takakura, Keiko  
 PATENT ASSIGNEE(S): Nitto Denko Corp., Japan; Toyama Chemical Co.,  
 Ltd.  
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.  
 CODEN: JKKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002029969	A2	20020129	JP 2000-215459	20000717

PRIORITY APPLN. INFO.: JP 2000-215459 20000717  
 OTHER SOURCE(S): MARPAT 136:139831  
 AB The invention relates to a transdermal compn. contg. a 1,2-ethanediol  
 deriv. as an active ingredient 0.5-60 % in an adhesive layer  
 including a  
 drug release-controlling layer formed on a base material, wherein the  
 compn. provides sufficient pharmaceutical effect without causing skin  
 irritation. An adhesive transdermal compn. was prepd. from an  
 adhesive  
 compn. contg. (R)-1-((Benzo[b]thiophene-5-yl)-2-[2-(N,N-  
 diethylamino)ethoxy]ethanol 5, polyisobutylene rubber 75, and iso-Pr  
 myristate 20 %, ultrahigh-mol.-wt. polyethylene porous film as a drug  
 release-controlling layer, and a polyester nonwoven fabric/polyester  
 base.  
 IT 392233-08-8 392233-09-9  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (adhesive transdermal compns. contg. 1,2-ethanediol derivs.)  
 RN 392233-08-8 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-  
 (9CI) (CA INDEX NAME)




RN 392233-09-9 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
 (.alpha.R)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 Absolute stereochemistry.




L7 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001:933321 CAPLUS  
 DOCUMENT NUMBER: 137:201198  
 TITLE: Synthesis of new medicine of Alzheimer disease  
 (T-588)  
 AUTHOR(S): Xiong, Fei; Chen, Chun  
 CORPORATE SOURCE: Peop. Rep. China  
 SOURCE: Huadong Shifan Daxue Xuebao, Ziran Kexueban  
 (3), 109-112  
 CODEN: HSXKEO; ISSN: 1000-5641  
 Huadong Shifan Daxue Chubanshe  
 PUBLISHER: Journal  
 DOCUMENT TYPE: Chinese  
 LANGUAGE: Chinese  
 OTHER SOURCE(S): CASREACT 137:201198  
 GI



AB Title compd. was synthesized from 5-Formylbenzo[b]thiophene via  
 optical  
 resolu. of key intermediate I, further ring opening, esterification,  
 hydroxy group protection, redn., condensation, giving the product  
 with  
 high yield and optical activity.  
 IT 142935-03-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis of new medicine of Alzheimer disease (T-588))  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L7 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)






L7 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001:688751 CAPLUS  
 DOCUMENT NUMBER: 136:48348  
 TITLE: Ameliorative effects of a cognitive enhancer, T-588, on place learning deficits induced by transient forebrain ischemia in rats  
 AUTHOR(S): Nakada, Y.; Tamura, R.; Kuriwaki, J.-I.; Kimura, T.; Uwano, T.; Nishijo, H.; Ono, T.  
 CORPORATE SOURCE: Faculty of Medicine, Department of Physiology, Toyama Medical and Pharmaceutical University, Toyama, 930-0194, Japan  
 SOURCE: Physiology & Behavior (2001), 74(1/2), 227-235  
 CODEN: PHEHA4; ISSN: 0031-9384  
 PUBLISHER: Elsevier Science Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB In the present study, we investigated the effect of (1R)-1-benzo[b]thiophen-5-yl-2-[2-(diethylamino)ethoxy]ethan-1-ol hydrochloride (T-588), a newly synthesized cognitive enhancer, on place learning deficits in rats with damage selective to the hippocampal CA1 subfield induced by transient forebrain ischemia. Three weeks after the ischemic insult, T-588 was daily administered (0.3 or 3.0 mg/kg/day po). Place learning was tested in a task in which the rat was required to alternatively visit two places located diametrically opposite each other in an open field. The ischemic rats without the treatment of T-588 displayed severe learning impairment in this task; their performance level was significantly inferior to that of the sham-operated rats. The treatment of T-588 improved dose-dependently the task performance in ischemic rats, although no apparent protective effects on ischemic damage were found histol. These results suggested that T-588 has ameliorative effects on learning deficits induced by brain ischemia, which could be produced through enhancement of residual cognitive functions.  
 IT 142935-03-3, T-588  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 by (ameliorative effects of T-588 on place learning deficits induced by transient forebrain ischemia in rats)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L7 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001:454295 CAPLUS  
 DOCUMENT NUMBER: 135:236337  
 TITLE: Effects of T-588, a cognitive enhancer compound, on synaptic plasticity in the dentate gyrus of freely moving rats  
 AUTHOR(S): Yamaguchi, Hidetoshi; Tamura, Ryoi; Kuriwaki, Jun-ichi; Eifuku, Satoshi; Ono, Taketoshi  
 CORPORATE SOURCE: Department of Physiology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan  
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (2001), 298(1), 354-361  
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB (1R)-1-benzo[b]thiophen-5-yl-2-[2-(diethylamino)ethoxy]ethan-1-ol hydrochloride (T-588) is a compd. for the treatment of neurodegenerative disorders, including Alzheimer's disease and cerebrovascular diseases. T-588 reportedly alleviates learning and memory deficits in animal models of dementia. In the present study, we investigated the effects of T-588 on the induction and decay of long-term potentiation (LTP) and on the responses to paired-pulse (pp) stimulation in freely moving rats. Perforant path-evoked field potentials were recorded in the dentate gyrus by chronically implanted electrodes. LTP was induced by high-frequency stimulation 30 min after oral administration of T-588 (0.3 or 3 mg/kg). T-588 significantly augmented the increase in population spike amplitude and field excitatory postsynaptic potential slope after LTP induction. T-588 also prolonged the decay of augmented population spike amplitude, but had no significant effect on the response to pp stimulation. These results suggest that T-588 facilitates long-term synaptic plasticity, but not short-term synaptic plasticity in the dentate gyrus of freely moving rats. The effect of T-588 on long-term synaptic plasticity may contribute to the alleviation of learning and memory dysfunction seen in animal models.  
 IT 142935-03-3, T-588


L7 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L7 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (effects of T-588 on synaptic plasticity in dentate gyrus of freely moving rats)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




● HCl


REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2000:900603 CAPLUS  
DOCUMENT NUMBER: 134:42057  
TITLE: Preparation of N-alkoxyalkyl-N,N-dialkylamine derivatives as remedies for neurodegenerative diseases  
INVENTOR(S): Ono, Satoshi; Saitoh, Akihito; Iwakami, Nohoru; Nakagawa, Masayuki; Yamaguchi, Sumie  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 140 pp.  
CODEN: P1XXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE  
WO 2000076957 A1 20001221 WO 2000-JP3748 20000609  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
EP 1186594 A1 20020313 EP 2000-935600 20000609  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO  
BR 2000011505 A 20020820 BR 2000-11505 20000609  
NO 2001006029 A 20011210 NO 2001-6029 20011210  
PRIORITY APPLN. INFO.: JP 1999-165879 A 19990611  
WO 2000-JP3748 W 20000609  
OTHER SOURCE(S): MARPAT 134:42057  
GI




L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of N-alkoxyalkyl-N,N-dialkylamine derivs. as remedies for neurodegenerative diseases)  
RN 313058-89-8 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-yloxy)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 313058-90-1 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-yloxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 313058-92-3 CAPLUS  
CN 2-Propanamine, N-[2-(2-benzo[b]thien-5-yloxy)ethyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 313058-93-4 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(2-methylbenzo[b]thien-5-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 313058-98-9 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-yloxy)-N,N-diethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
AB The title compds. I [R1 and R2 are each hydrogen, halogeno, or the like; A = (CR5R6)m; T = (CR7R8)n; R3 and R4 are each optionally substituted alkyl, cycloalkyl, or aralkyl; R5, R6, R7 and R8 are each hydrogen or alkyl; ring D is a five- or six-membered heterocycle or a hydrocarbon ring; m is 1 to 5; and n is 1 to 6] are prepd.  
N-[2-(2-benzo[b]thiophen-5-yloxy)ethyl]-N,N-diethylamine oxalic acid salt at 0.1 .mu.M gave 58% inhibition of 4-hydroxynonenal-induced death of nerve cells. Formulations are given.


IT 313058-89-8P 313058-90-1P 313058-92-3P  
313058-93-4P 313058-98-9P 313059-02-8P  
313059-04-0P 313059-06-2P 313059-07-3P  
313059-08-4P 313059-12-0P 313059-13-1P  
313059-15-3P 313059-16-4P 313059-17-5P  
313059-19-7P 313059-20-0P 313059-21-1P  
313059-22-2P 313059-24-4P 313059-25-5P  
313059-27-7P 313059-29-9P 313059-30-2P  
313059-31-3P 313059-32-4P 313059-33-5P  
313059-35-7P 313059-37-9P 313059-38-0P  
313059-40-4P 313059-42-6P 313059-43-7P  
313059-44-8P 313059-45-9P 313059-46-0P  
313059-48-2P 313059-49-3P 313059-50-6P  
313059-51-7P 313059-53-9P 313059-54-0P  
313059-56-2P 313059-57-3P 313059-58-4P  
313059-59-5P 313059-60-8P 313059-61-9P  
313059-62-0P 313059-65-3P 313059-66-4P  
313059-69-7P 313059-70-0P 313059-71-1P  
313059-72-2P 313059-73-3P 313059-74-4P  
313059-75-5P 313059-76-6P 313059-77-7P  
313059-78-8P 313059-79-9P 313059-82-4P  
313059-83-5P 313059-85-7P 313059-86-8P  
313059-87-9P 313059-88-0P 313059-89-1P  
313059-90-4P 313059-95-9P 313059-96-0P  
313059-97-1P 313059-98-2P 313059-99-3P  
313060-00-3P 313060-01-4P 313060-13-8P  
313060-14-9P 313060-16-1P 313060-18-3P  
313060-19-4P 313060-20-7P 313060-21-8P  
313060-23-0P 313060-24-1P 313060-25-2P  
313060-26-3P 313060-28-5P 313060-29-6P  
313060-30-9P 313060-31-0P 313060-32-1P  
313060-33-2P 313060-34-3P 313060-35-4P  
313060-36-5P 313060-37-6P 313060-38-7P  
313060-39-8P 313060-40-1P 313060-41-2P  
313060-42-3P 313060-43-4P 313060-44-5P  
313060-45-6P 313060-46-7P 313060-47-8P  
313060-48-9P 313060-49-0P 313060-50-3P  
313060-51-4P 313060-52-5P 313060-58-1P  
313060-59-2P 313060-60-5P 313060-61-6P  
313060-62-7P 313060-63-8P 313060-64-9P  
313060-65-0P 313060-66-1P 313060-67-2P  
313060-68-3P 313060-69-4P 313060-70-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 1

CRN 313058-89-8  
CMF C16 H23 N O S



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313059-02-8 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(2-methylbenzo[b]thien-5-yl)ethoxy]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313058-93-4  
CMF C17 H25 N O S




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 313059-04-0 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-yloxy)-N,N-dimethyl-, hydrochloride

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 313059-06-2 CAPLUS  
CN 2-Propanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-(1-methylethyl)-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 313059-07-3 CAPLUS  
CN Benzenemethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-methyl-  
(9CI) (CA INDEX NAME)




RN 313059-08-4 CAPLUS  
CN Benzenemethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-methyl-,  
ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 313059-07-3  
CMF C20 H23 N O S

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313059-16-4 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-7-ylethoxy)-N,N-dimethyl- (9CI) (CA  
INDEX NAME)



RN 313059-17-5 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]-,  
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313059-15-3  
CMF C16 H22 F N O S




GM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 313059-19-7 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-7-ylethoxy)-N,N-dimethyl-,  
hydrochloride  
(9CI) (CA INDEX NAME)




CM 2

CRN 144-62-7  
CMF C2 H2 04




RN 313059-12-0 CAPLUS  
CN Ethanamine, N,N-dimethyl-2-[2-(2-phenylbenzo[b]thien-5-yl)ethoxy]-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 313059-13-1 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(2-phenylbenzo[b]thien-5-yl)ethoxy]-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 313059-15-3 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]-  
(9CI)  
(CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 313059-20-0 CAPLUS  
CN Benzo[b]thiophene-2-carboxylic acid,  
5-[2-[2-(diethylamino)ethoxy]ethyl]-  
(9CI) (CA INDEX NAME)




RN 313059-21-1 CAPLUS  
CN Benzo[b]thiophene-2-carboxylic acid,  
5-[2-[2-(diethylamino)ethoxy]ethyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 313059-22-2 CAPLUS  
CN Benzo[h]thiophene-2-carboxamide, 5-[2-[2-(diethylamino)ethoxy]ethyl]-  
(9CI) (CA INDEX NAME)




RN 313059-24-4 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(6-methoxybenzo[b]thien-5-yl)ethoxy]-  
(9CI)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(CA INDEX NAME)




RN 313059-26-5 CAPLUS  
CN Ethanamine, 2-[2-(4-fluorobenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl- (9CI)  
(CA INDEX NAME)



RN 313059-27-7 CAPLUS  
CN Ethanamine, 2-[2-(6-methoxybenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl- (9CI)  
(CA INDEX NAME)




RN 313059-29-9 CAPLUS  
CN Ethanamine, 2-[2-(4-chlorobenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl- (9CI)  
(CA INDEX NAME)



RN 313059-30-2 CAPLUS  
CN Ethanamine, 2-[2-(4-fluorobenzo[b]thien-7-yl)ethoxy]-N,N-dimethyl- (9CI)  
(CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 313059-37-9 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(6-methoxybenzo[b]thien-5-yl)ethoxy]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313059-24-4  
CMF C17 H25 N O2 S



CM 2


CRN 144-62-7  
CMF C2 H2 O4




RN 313059-38-0 CAPLUS  
CN Ethanamine, 2-[2-(4-fluorobenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313059-25-5  
CMF C14 H18 F N O S




L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313059-31-3 CAPLUS  
CN Ethanamine, 2-[2-(6-chlorobenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl- (9CI)  
(CA INDEX NAME)



RN 313059-32-4 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(6-fluorobenzo[b]thien-7-yl)ethoxy]- (9CI)  
(CA INDEX NAME)



RN 313059-33-5 CAPLUS  
CN Ethanamine, 2-[2-(5,7-difluorobenzo[b]thien-6-yl)ethoxy]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 313059-35-7 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-yl-1-methylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 313059-40-4 CAPLUS  
CN Ethanamine, 2-[2-(6-methoxybenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 313059-42-6 CAPLUS  
CN Ethanamine, 2-[2-(4-chlorobenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 313059-43-7 CAPLUS  
CN Ethanamine, 2-[2-(4-fluorobenzo[b]thien-7-yl)ethoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)





● HCl

RN 313059-44-8 CAPLUS  
CN Ethanamine, 2-[(2-(6-chlorobenzo[b]thien-5-yl)ethoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 313059-45-9 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[(2-(6-fluorobenzo[b]thien-7-yl)ethoxy)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 313059-46-0 CAPLUS  
CN Ethanamine, 2-[(2-{5,7-difluorobenzo[b]thien-6-yl}ethoxy)-N,N-diethyl-, hydrochloride (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)-1-methylethyl]methylamino]- (9CI) (CA INDEX NAME)



RN 313059-53-9 CAPLUS  
CN 2-Propyn-1-amine, N-{2-(2-benzo[b]thien-5-ylethoxy)ethyl}-N-methyl- (9CI) (CA INDEX NAME)



RN 313059-54-0 CAPLUS  
CN Ethanol, 2,2'-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]imino]bis- (9CI) (CA INDEX NAME)





RN 313059-56-2 CAPLUS  
CN 1-Propanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-propyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1



CRN 313059-49-3  
CMF C18 H27 N O S

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 313059-48-2 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-yl-1-methylethoxy)-N,N-diethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 313059-49-3 CAPLUS  
CN 1-Propanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 313059-50-6 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)



RN 313059-51-7 CAPLUS

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313059-57-3 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313059-50-6  
CMF C15 H21 N O2 S



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313059-58-4 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)-1-methylethyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CRN 313059-51-7  
 CMF C16 H23 N O2 S



CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4




RN 313059-59-5 CAPLUS  
 CN 2-Propyn-1-amine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 313059-60-8 CAPLUS  
 CN Ethanol, 2,2'-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]imino]bis-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 313059-61-9 CAPLUS  
 CN Ethanol, 2-[[3-(2-benzo[b]thien-5-ylethoxy)propyl]methylamino]- (9CI)  
 (CA INDEX NAME)




RN 313059-62-0 CAPLUS  
 CN Ethanol, 2-[[5-(2-benzo[b]thien-5-ylethoxy)pentyl]methylamino]- (9CI)  
 (CA INDEX NAME)



RN 313059-65-3 CAPLUS  
 CN Ethanol, 2-[[3-(2-benzo[b]thien-5-ylethoxy)propyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1  
 CRN 313059-61-9  
 CMF C16 H23 N O2 S

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4



RN 313059-66-4 CAPLUS  
 CN Ethanol, 2-[[5-(2-benzo[b]thien-5-ylethoxy)pentyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1  
 CRN 313059-62-0  
 CMF C18 H27 N O2 S




CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4




RN 313059-69-7 CAPLUS  
 CN 2-Propanamine, 1-(2-benzo[b]thien-5-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 313059-70-0 CAPLUS  
 CN 1-Propanamine, 3-(2-benzo[b]thien-5-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 313059-71-1 CAPLUS  
 CN 1-Pentanamine, 5-(2-benzo[b]thien-5-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 313059-72-2 CAPLUS  
 CN 1-Propanamine, 3-(2-benzo[b]thien-5-ylethoxy)-N,N-diethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1  
 CRN 313059-70-0  
 CMF C17 H25 N O S




CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313059-73-3 CAPLUS  
CN 1-Pentanamine, 5-(2-benzo[b]thien-5-ylethoxy)-N,N-diethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 313059-74-4 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-7-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 313059-75-5 CAPLUS  
CN Benzenemethanamine, N-[2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 313059-76-6 CAPLUS  
CN Ethanamine, 2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313059-83-5 CAPLUS  
CN 1,2-Ethanediamine, N-[2-(2-benzo[b]thien-4-ylethoxy)ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 313059-85-7 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-7-ylethoxy)-N,N-diethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313059-74-4  
CMF C16 H23 N O S




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 313059-86-8 CAPLUS  
CN Benzenemethanamine, N-[2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]ethyl]-N-methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313059-77-7 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-4-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 313059-78-8 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-6-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 313059-79-9 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-ylethoxy)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 313059-82-4 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-4-ylethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 1

CRN 313059-75-5  
CMF C20 H22 F N O S



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313059-87-9 CAPLUS  
CN Ethanamine, 2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]-N,N-dimethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313059-76-6  
CMF C14 H18 F N O S



CM 2


CRN 144-62-7  
CMF C2 H2 O4








L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-16-1 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-4-yloxy)ethyl]methylamino]-, hydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 313060-18-3 CAPLUS  
CN Ethanol, 2-[[2-(2-fluorobenzo[b]thien-5-yl)ethoxy]ethyl]methylamino]- (9CI) (CA INDEX NAME)




RN 313060-19-4 CAPLUS  
CN Ethanol, 2-[[2-(2-(6-fluorobenzo[b]thien-7-yl)ethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)




L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 313060-25-2 CAPLUS  
CN Ethanol, 2-[[2-(2-(6-fluoro-7-methoxybenzo[b]thien-5-yl)ethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)



RN 313060-26-3 CAPLUS  
CN Ethanol, 2-[[2-(2-(6-fluoro-7-methylbenzo[b]thien-5-yl)ethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)




RN 313060-28-5 CAPLUS  
CN Ethanol, 2-[[2-(2-(2-fluorobenzo[b]thien-5-yl)ethoxy)ethyl]methylamino]-, ethanediolate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CBN 313060-18-3  
CMF C15 H20 F N O2 S

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 313060-20-7 CAPLUS  
CN Ethanol, 2-[[2-(2-(5,7-difluorobenzo[b]thien-6-yl)ethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)



RN 313060-21-8 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-7-yloxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)




RN 313060-23-0 CAPLUS  
CN Benzo[b]thiophene-7-ol, 6-fluoro-5-[2-(2-(2-hydroxyethyl)methylamino)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 313060-24-1 CAPLUS  
CN Ethanol, 2-[[2-(2-(6-fluoro-7-(methylthio)benzo[b]thien-5-yl)ethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2

CBN 144-62-7  
CMF C2 H2 O4




RN 313060-29-6 CAPLUS  
CN Ethanol, 2-[[2-(2-(6-fluorobenzo[b]thien-7-yl)ethoxy)ethyl]methylamino]-, hydrochloride (9CI) (CA INDEX NAME)



• HCl


RN 313060-30-9 CAPLUS  
CN Ethanol, 2-[[2-(2-(5,7-difluorobenzo[b]thien-6-yl)ethoxy)ethyl]methylamino]-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 313060-31-0 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-7-ylethoxy)ethyl]methylamino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 313060-32-1 CAPLUS  
CN 1-Propanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)



RN 313060-33-2 CAPLUS  
CN 2-Propanol, 1-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313060-37-6 CAPLUS  
CN 2-Propanol, 1-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313060-33-2  
CMF C16 H23 N O2 S



CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 313060-38-7 CAPLUS  
CN 1-Propanol, 3-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 313060-34-3  
CMF C16 H23 N O2 S


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 313060-34-3 CAPLUS  
CN 1-Propanol, 3-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]- (9CI) (CA INDEX NAME)




RN 313060-35-4 CAPLUS  
CN Ethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 313060-36-5 CAPLUS  
CN 1-Propanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313060-32-1  
CMF C16 H23 N O2 S



L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313060-39-8 CAPLUS  
CN Benzenemethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 313060-40-1 CAPLUS  
CN Benzenemethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 313060-41-2 CAPLUS  
CN Benzenemethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-4-fluoro-N-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-42-3 CAPLUS  
CN Benzenemethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-methyl-4-  
nitro- (9CI) (CA INDEX NAME)



RN 313060-43-4 CAPLUS  
CN Cyclopropanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-methyl-  
(9CI) (CA INDEX NAME)



RN 313060-44-5 CAPLUS  
CN 2-Propyn-1-amine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-ethyl-  
(9CI) (CA INDEX NAME)




RN 313060-45-6 CAPLUS  
CN Cyclopropanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-ethyl-  
(9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 1

CRN 313060-40-1  
CMF C21 H25 N O2 S



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313060-49-0 CAPLUS  
CN Benzenemethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-4-fluoro-N-  
methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313060-41-2  
CMF C20 H22 F N O S




CM 2


CRN 144-62-7  
CMF C2 H2 O4



L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-46-7 CAPLUS  
CN Benzenemethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-cyclopropyl-  
(9CI) (CA INDEX NAME)



RN 313060-47-8 CAPLUS  
CN Benzenemethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-2-propynyl-,  
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313060-39-8  
CMF C22 H23 N O S



CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 313060-48-9 CAPLUS  
CN Benzenemethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-4-methoxy-N-  
methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 313060-50-3 CAPLUS  
CN Benzenemethanamine,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-methyl-4-  
nitro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313060-42-3  
CMF C20 H22 N2 O3 S




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 313060-51-4 CAPLUS  
CN Cyclopropanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-methyl-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 313060-52-5 CAPLUS  
CN 2-Propyn-1-amine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-ethyl-,  
hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl


RN 313060-58-1 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 313060-59-2 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, acetate (ester), ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 313060-58-1  
CMF C17 H23 N O3 S



CM 2


CRN 144-62-7  
CMF C2 H2 O4

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 313060-64-9 CAPLUS  
CN Carbonic acid, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 313060-65-0 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, benzoate (ester), hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 313060-66-1 CAPLUS  
CN Benzo[b]thiophene-3-methanol, 5-[2-[2-[(2-hydroxyethyl)methylamino]ethoxy]ethyl]-.alpha..alpha.-dimethyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-60-5 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]ethyl ester (9CI) (CA INDEX NAME)



RN 313060-61-6 CAPLUS  
CN Carbonic acid, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]ethyl ester (9CI) (CA INDEX NAME)




RN 313060-62-7 CAPLUS  
CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 313060-63-8 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 313060-67-2 CAPLUS  
CN Benzo[b]thiophene-3-methanol, 5-[2-[2-[(2-hydroxyethyl)methylamino]ethoxy]ethyl]-.alpha..alpha.-dimethyl-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313060-66-1  
CMF C18 H27 N O3 S




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 313060-68-3 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[2-(2-(3-pyridinyl)benzo[b]thien-5-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 313060-69-4 CAPLUS


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN Ethanamine,  
 N,N-diethyl-2-[2-[(3-pyridinyl)benzo[b]thien-5-yl]ethoxy]-,  
 ethanedioate (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 313060-68-3  
 CMF C21 H26 N2 O S



CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4




RN 313060-70-7 CAPLUS  
 CN Ethanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]methylamino]-,  
 (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 313059-50-6  
 CMF C15 H21 N O2 S




CM 2  
 CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-74-1 CAPLUS  
 CN Acetamide, 2-(2-benzo[b]thien-4-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 313060-75-2 CAPLUS  
 CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 313060-76-3 CAPLUS  
 CN Acetamide, 2-(3-benzo[b]thien-5-ylpropoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 313060-79-6 CAPLUS  
 CN Acetamide, 2-(2-benzo[b]thien-4-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 313060-71-8P 313060-72-9P 313060-73-0P  
 313060-74-1P 313060-75-2P 313060-76-3P  
 313060-79-6P 313060-80-9P 313060-81-0P  
 313060-82-1P 313060-83-2P 313060-84-3P  
 313060-85-4P 313060-86-5P 313060-87-6P  
 313060-88-7P 313060-89-8P 313060-90-1P  
 313060-91-2P 313060-92-3P 313060-93-4P  
 313060-95-6P 313060-96-7P 313060-97-8P  
 313060-98-9P 313061-00-6P 313061-01-7P  
 313061-02-8P 313061-03-9P 313061-04-0P  
 313061-05-1P 313061-06-2P 313061-16-4P  
 313061-17-5P 313061-18-6P 313061-19-7P  
 313061-20-0P 313061-21-1P 313061-22-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (prepn. of N-alkoxyalkyl-N,N-dialkylamine derivs. as remedies for  
 neurodegenerative diseases)  
 RN 313060-71-8 CAPLUS  
 CN Acetamide, N,N-diethyl-2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 313060-72-9 CAPLUS  
 CN Acetamide, 2-(2-benzo[b]thien-7-ylethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 313060-73-0 CAPLUS  
 CN Acetamide, 2-(2-benzo[b]thien-7-ylethoxy)-N,N-diethyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-80-9 CAPLUS  
 CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-(dimethylamino)ethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 313060-81-0 CAPLUS  
 CN Acetamide, N-(2-hydroxyethyl)-N-methyl-2-[2-(2-methylbenzo[b]thien-5-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 313060-82-1 CAPLUS  
 CN Acetamide, N-(2-hydroxyethyl)-2-[2-(6-methoxybenzo[b]thien-5-yl)ethoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 313060-83-2 CAPLUS  
 CN Acetamide, 2-[2-(6-fluorobenzo[b]thien-5-yl)ethoxy]-N-(2-hydroxyethyl)-N-


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-84-3 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-ethyl-N-(2-hydroxyethyl)-(9CI) (CA INDEX NAME)



RN 313060-85-4 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-5-ylethoxy)-N-(2-hydroxyethyl)-N-(phenylmethyl)-(9CI) (CA INDEX NAME)




RN 313060-86-5 CAPLUS  
CN Acetamide, 2-(3-benzo[b]thien-5-ylpropoxy)-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)




RN 313060-87-6 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-6-ylethoxy)-N-methyl-N-(2-(triphenylmethoxy)ethyl)-(9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-92-3 CAPLUS  
CN Acetamide, 2-[2-(5,7-difluorobenzo[b]thien-6-yl)ethoxy]-N-methyl-N-(2-(triphenylmethoxy)ethyl)-(9CI) (CA INDEX NAME)



RN 313060-93-4 CAPLUS  
CN Acetamide, 2-(2-benzo[b]thien-7-ylethoxy)-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)




RN 313060-95-6 CAPLUS  
CN Acetamide, 2-[2-(6-fluoro-7-hydroxybenzo[b]thien-5-yl)ethoxy]-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)




RN 313060-96-7 CAPLUS


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313060-88-7 CAPLUS  
CN Acetamide, 2-[2-benzo[b]thien-4-ylethoxy]-N-methyl-N-(2-(triphenylmethoxy)ethyl)-(9CI) (CA INDEX NAME)



RN 313060-89-8 CAPLUS  
CN Acetamide, 2-[2-(5-methoxybenzo[b]thien-6-yl)ethoxy]-N-methyl-N-(2-(triphenylmethoxy)ethyl)-(9CI) (CA INDEX NAME)




RN 313060-90-1 CAPLUS  
CN Acetamide, 2-[2-(2-fluorobenzo[b]thien-5-yl)ethoxy]-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)




RN 313060-91-2 CAPLUS  
CN Acetamide, 2-[2-(6-fluorobenzo[b]thien-7-yl)ethoxy]-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN Acetamide, 2-[2-(6-fluoro-7-(methylthio)benzo[b]thien-5-yl)ethoxy]-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)



RN 313060-97-8 CAPLUS  
CN Acetamide, 2-[2-(6-fluoro-7-methoxybenzo[b]thien-5-yl)ethoxy]-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)




RN 313060-98-9 CAPLUS  
CN Acetamide, 2-[2-(6-fluoro-7-methylbenzo[b]thien-5-yl)ethoxy]-N-(2-hydroxyethyl)-N-methyl-(9CI) (CA INDEX NAME)




RN 313061-00-6 CAPLUS  
CN Formamide, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-(2-hydroxy-1-methylethyl)-(9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313061-01-7 CAPLUS  
CN Formamide,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-(2-hydroxypropyl)-  
(9CI) (CA INDEX NAME)



RN 313061-02-8 CAPLUS  
CN Formamide,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-(3-hydroxypropyl)-  
(9CI) (CA INDEX NAME)




RN 313061-03-9 CAPLUS  
CN Formamide,  
N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-(2-methoxyethyl)-  
(9CI) (CA INDEX NAME)




RN 313061-04-0 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-ylethoxy)-N-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313061-18-6 CAPLUS  
CN 2-Propanol, 1-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI)  
(CA INDEX NAME)



RN 313061-19-7 CAPLUS  
CN 1-Propanol, 3-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI)  
(CA INDEX NAME)




RN 313061-20-0 CAPLUS  
CN 1-Propanol, 2-[[2-(2-benzo[b]thien-5-ylethoxy)ethyl]amino]- (9CI)  
(CA INDEX NAME)




RN 313061-21-1 CAPLUS  
CN Ethanamine, 2-(2-benzo[b]thien-5-ylethoxy)-N-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 313061-05-1 CAPLUS  
CN Benzo[b]thiophene-2-methanol,  
.alpha.,.alpha.-dimethyl-5-(6,10,10,11,11-pentamethyl-3,9-dioxo-6-sza-10-siladodec-1-yl)- (9CI) (CA INDEX NAME)



RN 313061-06-2 CAPLUS  
CN Boronic acid, {5-[2-(diethylamino)ethoxy]ethyl}benzo[b]thien-2-yl]-  
(9CI) (CA INDEX NAME)




RN 313061-16-4 CAPLUS  
CN 2-Propyl-1-amine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 313061-17-5 CAPLUS  
CN Cyclopropanamine, N-[(2-benzo[b]thien-5-ylethoxy)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 313061-22-2 CAPLUS  
CN Ethanamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-2-methoxy- (9CI)  
(CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:434963 CAPLUS

DOCUMENT NUMBER: 133:172030

TITLE: T-588 inhibits astrocyte apoptosis via mitogen-activated protein kinase signal pathway  
AUTHOR(S): Takuma, K.; Fujita, T.; Kimura, Y.; Tanabe, M.; Yamamuro, A.; Lee, E.; Mori, K.; Koyama, Y.;

Baba, A.;

CORPORATE SOURCE: Matsuda, T.  
Faculty of Pharmaceutical Sciences, Department of Analytical Chemistry, Kobe Gakuin University, Nishi-ku, Ikawadani-cho, Kobe, 651-2180, Japan  
European Journal of Pharmacology (2000), 399(1), 1-8

CODEN: EUPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effect of (1R)-1-benzo[b]thiophen-5-yl-2-[2-(diethylamino)ethoxy]ethan-1-ol hydrochloride (T-588), a cognition enhancer, on reperfusion injury

was studied in cultured rat astrocytes. T-588 at 1-10 .mu.M partially protected astrocytes against reperfusion injury after exposure to Ca2+-free medium or hydrogen peroxide. Nerve growth factor (NGF) had a

similar protective effect. Addn. of both T-588 and NGF resulted in complete protection against Ca2+ reperfusion injury. T-588 did not stimulate NGF prodn. in astrocytes. The effect of T-588 on Ca2+ reperfusion injury including apoptosis was inhibited by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor 2'-amino-3'-methoxyflavone (PD98059), but not

by the phosphoinositide 3-kinase inhibitor wortmannin. The effect of NGF was inhibited by PD98059 and wortmannin. T-588 stimulated rapidly the phosphorylation of ERK, but did not affect that of Akt in astrocytes. These findings suggest that the ERK MAP kinase pathway has a role in the protective effects of T-588 and NGF.

IT 142935-03-3, T-588

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological

study); USES

(Uses)


(T-588 inhibits astrocyte apoptosis via mitogen-activated protein kinase signal pathway)

RN 142935-03-3 CAPLUS

CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:142165 CAPLUS

DOCUMENT NUMBER: 132:303377

TITLE: T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in

wobbler mouse motoneuron disease

AUTHOR(S): Ikeda, K.; Iwasaki, Y.; Kinoshita, M.; Marubuchi, S.;

Ono, S.

CORPORATE SOURCE: Maguro-ku, Ohashi, 2-17-6, Fourth Department of Internal Medicine, Toho University Ohashi

Hospital,

Tokyo, Japan

SOURCE: Brain Research (2000), 858(1), 84-91

CODEN: ERREAP; ISSN: 0006-8993

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588) enhances acetylcholine release from the frontal cortex and hippocampus in rats, and can ameliorate cognitive

dysfunction in various amnesia models of rodents. T-588 protects rat cerebellar granule cells from glutamate neurotoxicity in culture. This agent

also inhibits facilitation in the crayfish neuromuscular junction and mammalian cerebellum. Clin. trials of T-588 are underway in patients with

Alzheimer's disease. The authors attempted to det. whether T-588 treatment ameliorates neuromuscular dysfunction in the wobbler

mouse, an animal model of motoneuron disease (MND). After the initial

diagnosis of MND at the age of 3-4 wk, wobbler mice were orally administered

T-588 (3, 10, 30 mg/kg) or vehicle daily for 4 wk in a blinded fashion. The

authors compared symptomatic, pathol. and biochem. changes among the groups. In

comparison with vehicle, T-588 administration potentiated grip strength, attenuated forelimb contracture and increased the wt. of the biceps

muscles. T-588-treated mice had retarded denervation muscle atrophy and

elevated activities of choline acetyltransferase (ChAT) or lactate dehydrogenase in the biceps muscles. T-588 treatment also enhanced

ChAT activities and promoted formation of cAMP in the cervical cord. Pharmacokinetic study also showed that T-588 was transported

efficiently into the cerebrum and spinal cord following oral administration.

Thus, T-588 treatment delayed the progression of wobbler murine MND. The

authors' findings suggest that this agent has therapeutic potential in

human motor neuropathy or MND.

L7 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

IT 142935-03-3, T-588

RL: BAC (Biological activity or effector, except adverse); BPR

(Biological process); BSU (Biological study, unclassified); THU (Therapeutic use);

BIOL (Biological study); PROC (Process); USES (Uses)

(novel neuroprotective agent T-588 attenuates symptomatic,

biochem. pathol. deterioration of muscle and spinal cord in wobbler mouse

motoneuron disease)


RN 142935-03-3 CAPLUS

CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-,

hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl



● HCl

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS


FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE



L7 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2000:94142 CAPLUS  
 DOCUMENT NUMBER: 132:23223  
 TITLE: Involvement of Hg2+-sensitive sulfhydryl groups  
 in  
 regulating noradrenaline release induced by  
 S-nitrosocysteine in rat brain slices  
 AUTHOR(S): Maekawa, M.; Satoh, S.; Murayama, T.; Nomura, Y.  
 CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences,  
 Department of Pharmacology, Hokkaido University, Sapporo,  
 Japan  
 SOURCE: Biochemical Pharmacology (2000), 59(7), 839-845  
 CODEN: BCPA6; ISSN: 0006-2952  
 PUBLISHER: Elsevier Science Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Nitric oxide has been shown to regulate neurotransmitter release.  
 Previously, the authors reported that S-nitrosothiols such as  
 S-nitrosocysteine (SNC) stimulate noradrenaline (NA) release in rat  
 hippocampus in vivo and in vitro. To examine the role of sulfhydryl  
 groups in SNC-induced NA release, the effects of metal ions such as  
 Hg2+  
 and N-ethylmaleimide (NEM, a sulfhydryl alkylating agent) on [3H]NA  
 release from labeled rat brain slices (hippocampus and cerebral  
 cortex)  
 were studied and compared with the effects of SNC. The addn. of 200  
 .mu.M  
 HgCl2, but not Pb2+, Zn2+, or Cd2+, stimulated [3H]NA release from  
 both  
 types of slices in the presence of extracellular CaCl2.  
 P-Chloromercuribenzoic acid (p-CMBA) also stimulated [3H]NA release.  
 NEM  
 stimulated [3H]NA release from both types of slices in the presence  
 and  
 absence of extracellular CaCl2. The effect of 200 .mu.M NEM was  
 enhanced,  
 but the effect of 200 .mu.M SNC was inhibited by co-addn. of 200  
 .mu.M  
 p-CMBA in the absence of extracellular CaCl2. The concn.-response  
 curve  
 of SNC shifted to the right after co-addn. of 200 .mu.M p-CMBA or 100  
 .mu.M HgCl2, although the effect of 200 .mu.M NEM was additive to the  
 effect of SNC. These findings demonstrate that SNC acts as a  
 sulfhydryl  
 agent on proteins that regulate NA release, and that SNC may share  
 the  
 same sulfhydryl groups with Hg compds. The effect of T-588  
 ((R)-(-)-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol  
 hydrochloride), a novel cognitive enhancer and a stimulator of NA  
 release,  
 was compared with the effects of sulfhydryl reagents.  
 IT 142935-03-3, T-588  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); BIOL (Biological study)


L7 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2000:91978 CAPLUS  
 DOCUMENT NUMBER: 132:203044  
 TITLE: Stimulation of noradrenaline release by T-588, a  
 cognitive enhancer, in PC12 cells  
 AUTHOR(S): Maekawa, Mutsuko; Ono, Satoshi; Narita, Hirokazu;  
 Murayama, Toshihiko; Nomura, Yasuyuki  
 CORPORATE SOURCE: Department of Pharmacology, Graduate School of  
 Pharmaceutical Sciences, Hokkaido University,  
 Sapporo,  
 SOURCE: Japanese Journal of Pharmacology (2000), 82(1),  
 59-66  
 CODEN: JJPAAZ; ISSN: 0021-5198  
 PUBLISHER: Japanese Pharmacological Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Previously, we reported that  
 (R)-(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-  
 diethylamino)ethoxy] ethanol hydrochloride (T-588), a novel putative  
 cognitive enhancer, stimulated noradrenaline (NA) release from rat  
 cerebral cortical slices. In this study, we investigated the  
 effects of  
 T-588 compared to other secretagogues on NA release from PC12 cells.  
 Addn. of as little as 10 .mu.M T-588 stimulated [3H]NA release in a  
 dose-dependent and an extracellular Ca2+-independent manner from PC12  
 cells. Ten micromolar ionomycin-300 .mu.M adenosine-5'-O-(gamma.-  
 thiotriphosphate)- and 10 .mu.M forskolin-induced extracellular  
 Ca2+-dependent [3H]-NA release was further enhanced by 30 .mu.M  
 T-588.  
 Cytosolic synaptophysin and 25-kDa synaptosome-assocd. protein  
 immunoreactivity was increased by addn. of T-588 in a dose-dependent  
 manner. Interestingly, increases in synaptic vesicle-related  
 proteins  
 triggered by T-588 had a 4-min lag time and were completely  
 dependent on  
 extracellular CaCl2. These findings suggest that T-588 stimulates NA  
 release from PC12 cells in a Ca2+-independent manner. T-588 also  
 induced  
 the translocation of synaptic vesicles in a Ca2+-dependent manner.  
 IT 142935-03-3, T-588  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); BIOL (Biological study)  
 (T-588 stimulation of noradrenaline release in PC12 cell)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L7 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 (involvement of Hg2+-sensitive sulfhydryl groups in regulating  
 noradrenaline release induced by S-nitrosocysteine in rat brain  
 slices  
 and comparison with T-588, novel cognitive enhancer and stimulator  
 of  
 noradrenaline release)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR  
 THIS  
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR  
 THIS  
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L7 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2000:45621 CAPLUS  
 DOCUMENT NUMBER: 132:26082  
 TITLE: T-588 for treatment of Alzheimer's disease  
 AUTHOR(S): Ono, Satoshi  
 CORPORATE SOURCE: General Res. Lab., Toyama Chem. Co., Ltd., Japan  
 SOURCE: Rinsho to Yakubutsu Chiryo (2000), 19(1), 50-52  
 CODEN: RYCHEI; ISSN: 0913-7505  
 PUBLISHER: Mikusu  
 DOCUMENT TYPE: Journal: General Review  
 LANGUAGE: Japanese  
 AB A review, with 5 refs., discussing the protective effect of a cerebral activator T-588, R(-)-1-(benzo[b]thiophen-5-yl)-2-[(N,N-diethylaminoethoxy)ethanol]HCl, on nerve cell and microglia.  
 IT 142935-03-3, T 588  
 RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (T-588 for treatment of Alzheimer's disease)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



● HCl

L7 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1999:796726 CAPLUS  
 DOCUMENT NUMBER: 132:88141  
 TITLE: Reduced facilitation and vesicular uptake in crustacean and mammalian neuromuscular junction by T-588, a neuroprotective compound  
 AUTHOR(S): Hirata, Kazunari; Nakagawa, Masaya; Urbano, J.; Rosato-Siri, Marcelo D.; Moreira, Jorge E.; Uchitel, Osvaldo D.; Sugimori, Mutsuyuki; Llinas, Rodolfo  
 CORPORATE SOURCE: Department of Physiology and Neuroscience, New York University School of Medicine, New York, NY, USA  
 10016, Proceedings of the National Academy of Sciences of the United States of America (1999), 96(25), 14588-14593  
 CODEN: PNASA6; ISSN: 0027-8424  
 PUBLISHER: National Academy of Sciences  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Bath application of compd. T-588, a neuroprotective agent, reduced paired-pulse and repetitive-pulse facilitation at mammalian and crustacean neuromuscular junctions. In addn., it reduced voltage-gated sodium and potassium currents in a use-dependent fashion, but had only a small effect on the presynaptic Ca2+ conductance. By contrast, it blocked FM 1-43 vesicular uptake but not its release, in both species. Postsynaptically, T-588 reduced acetylcholine currents at the mammalian junction in a voltage-independent manner, but had no effect on the crayfish glutamate junction. All of these effects were rapidly reversible and were obsd. at concns. close to the compd.'s acute protective level. We propose that this set of mechanisms, which reduces high-frequency synaptic transmission, is an important contributory factor in the neuroprotective action of T-588.  
 IT 142935-03-3, T-588  
 RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (neuroprotective action mechanism of T-588)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L7 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L7 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1999:404925 CAPLUS  
 DOCUMENT NUMBER: 131:54026  
 TITLE: Alkyl ether derivatives or salts for calcium antagonists  
 INVENTOR(S): Ono, Satoshi; Yamamoto, Hirohiko; Yamafuji, Tetsuo  
 PATENT ASSIGNEE(S): Nakagawa, Masaya; Saitoh, Akihito  
 SOURCE: Toyama Chemical Co., Ltd., Japan  
 PCT Int. Appl., 123 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931056	A1	19990624	WO 1998-JP5610	19981211
W: AU, BR, CA, CZ, HU, IN, KR, MX, NZ, PL, RO, SK, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11263773	A2	19990928	JP 1998-350904	19981210
AU 9915064	A1	19990705	AU 1999-15064	19981211
PRIORITY APPLN. INFO.:			JP 1997-362968	19971212
			WO 1998-JP5610	19981211

OTHER SOURCE(S): MARPAT 131:54026  
 AB Alkyl ether derivs. or salts, useful as excellent calcium antagonists, has a structure R1R2CH(CH2)mO(CH2)nR3 wherein R1 is (substituted) aryl or heterocycle, R2 is H or OH, R3 is -NR4R5 (R4 is cyclic amino, and R5 is alkyl, or R4 and R5 may form a cyclic amino), or a nitrogen-contg. satd. 6-membered ring having a bond from a carbon atom, m is 1 to 5, and n is 2 to 6. Thus, benzo[b]thiophene-5-carboxyaldehyde 15 g was reacted with 2-chloroethoxymethylmagnesium chloride (1.6 M in THF, 100 mL) at -30.degree. to give 1-benzo[b]thiophen-5-yl-2-(2-chloroethoxy)ethanol 15.6 g, 2.59 g of which was reacted with benzhydrylpiperazine in the presence of KI and CaCO3 to give 2-[(2-(4-benzhydrylpiperazino)ethoxy)-1-benzo[b]thiophen-5-yl]-1-ethanol 3.71 g, which was reacted with HCl to give a dihydrochloride salt, 11.5 g of which was mixed with starch 97 g, lactose 188.5 g to give a capsule dosage for calcium antagonists.  
 IT 227807-35-4P 227807-36-5P 227807-46-7P 227808-38-0P 227808-43-7P 227808-82-4P  
 RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of alkyl ether derivs. and salts for calcium antagonists)  
 RN 227807-35-4 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-[ethyl[1-(phenylmethyl)-3-pyrrolidinyl]amino]ethoxy]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 227807-36-5 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-[[1-(diphenylmethyl)-3-pyrrolidinyl]ethylamino]ethoxy]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 227807-46-7 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-[ethyl[1-[(2E)-3-phenyl-2-propenyl]-3-pyrrolidinyl]amino]ethoxy]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 2 HCl


RN 227808-38-0 CAPLUS  
 CN 3-Pyrrolidinamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-1-(diphenylmethyl)-N-ethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 227808-43-7 CAPLUS  
 CN 3-Pyrrolidinamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-ethyl-1-[(2E)-3-phenyl-2-propenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● 2 HCl

RN 227808-82-4 CAPLUS  
 CN 3-Pyrrolidinamine, N-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-N-ethyl-1-(phenylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 227808-81-3  
 CMF C25 H32 N2 O 5



CM 2

CRN 110-17-8  
 CMF C4 H4 O4


Double bond geometry as shown.



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

ACCESSION NUMBER: 1999:359982 CAPLUS  
 DOCUMENT NUMBER: 131:194134  
 TITLE: Effects of T-588, a newly synthesized cognitive enhancer, on hippocampal CA1 neurons in rat brain tissue slices  
 AUTHOR(S): Kimura, Tatsuo; Tamura, Ryo; Kurimoto, Hiroaki; Ono, Taketoshi  
 CORPORATE SOURCE: Faculty of Medicine, Department of Physiology, Toyama Medical and Pharmaceutical University, Toyama, Japan  
 SOURCE: Brain Research (1999), 831(1,2), 175-183  
 CODEN: BRREAP; ISSN: 0006-8993  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The effects of a newly synthesized cognitive enhancer, (-)-R-.alpha.-[[2-(diethylamino)ethoxy]methyl]benzo[b]thiophene-5-methanol hydrochloride (T-588), on the membrane properties of hippocampal CA1 neurons were investigated in a rat brain slice prep. T-588 produced a slow and long-lasting depolarization of CA1 neurons with an increase in membrane resistance; this action showed close similarity to that of acetylcholine (ACh). However, the action of T-588 was not affected by atropine, tetrodotoxin or DL-2-amino-5-phosphonovaleate, while the action of ACh was blocked by atropine. The estd. reversal potential of this T-588 effect was near -90 mV which is the reversal potential of potassium ions in CA1 neurons. In the whole-cell voltage-clamp study, T-588 produced a reversible block of the outward potassium current in CA1 neurons. T-588 did not block the afterhyperpolarization evoked by an intracellular current injection, while ACh suppressed it. These results suggest that T-588 has a direct effect on CA1 neurons independent of its cholinergic activity, resulting from blockade of a conductance carried predominantly by potassium ions.  
 IT 142935-03-3, T-588  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (effects of T-588, a newly synthesized cognitive enhancer, on hippocampal CA1 neurons in rat brain tissue slices)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

ACCESSION NUMBER: 1999:235734 CAPLUS  
DOCUMENT NUMBER: 131:39601  
TITLE: Effects of T-588, a novel cognitive enhancer, on ADP-ribosylation of Gs.alpha. by cholera toxin and cyclic AMP accumulation in rat cerebral cortex  
AUTHOR(S): Maekawa, M.; Miyazaki, H.; Ono, S.; Narita, H.; Murayama, T.; Nomura, Y.  
CORPORATE SOURCE: Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan  
SOURCE: Neurochemistry International (1999), 34(2), 149-155  
CODEN: NEUIDS; ISSN: 0197-0186  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB We investigated the effects of R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588), a novel cognitive enhancer, on trimetric GTP-binding proteins (G proteins) and cAMP accumulation in rat cerebral cortex. T-588 (0.1-1.0 mM) inhibited the ADP-ribosylation of .alpha. subunit of Gs in a concn.-dependent manner.  
Auto-ADP-ribosylation of CTX was not inhibited by T-588. The stimulatory effect of guanosine 5'-(3-O-thio)triphosphate (GTP.gamma.S) on CTX-catalyzed ADP-ribosylation was attenuated by adding T-588 in assay mixt. ADP-ribosylation of G1/Go by pertussis toxin was slightly inhibited by T-588. Isoproterenol-stimulated cAMP accumulation was inhibited by adding 3 mM T-588 to rat cerebral cortical slices. Next, we investigated the effects of isoproterenol and T-588 on GTP.gamma.S binding. Membranes were first incubated with or without isoproterenol and T-588 in the presence of 0.2 mM GTP.gamma.S, then cholera ext. preps. were prepd. from the washed membranes. Interestingly, the [32P]ADP-ribosylation of Gs.alpha. was enhanced not only by isoproterenol but also by T-588. Although the obtained results are apparently inconsistent, T-588 seems to interact with G proteins, specifically Gs.  
IT 142935-03-3, T-588  
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses) (effects of T-588, a novel cognitive enhancer, on ADP-ribosylation of GS.alpha. by cholera toxin and cAMP accumulation in rat cerebral cortex)  
RW 142935-03-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(diethylamino)ethoxy]methyl]-,

Absolute stereochemistry.




● HCl

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

ACCESSION NUMBER: 1998:682240 CAPLUS  
DOCUMENT NUMBER: 129:290055  
TITLE: Process for producing 2-(benzo[b]thiophen-5-yl)-2-hydroxyacetic acid derivatives as pharmaceutical intermediates  
INVENTOR(S): Yamamoto, Hirohiko; Yamafuji, Tetsuo; Yonezawa, Kenji;  
Saitoh, Akihito; Takamatsu, Tamotsu; Kotsubo, Hironori  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 35 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843967	A1	19981008	WO 1998-JP1436	19980330
W: AU, CA, CZ, HU, JP, KR, NZ, PL, RO, SK, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9865197	A1	19981022	AU 1998-65197	19980330
PRIORITY APPLN. INFO.: JP 1997-96668 19970331				
WO 1998-JP1436 19980330				
OTHER SOURCE(S): CASREACT 129:290055; MARPAT 129:290055				
GI				




AB The title compds. I [R1 = H, carboxy-protecting group; R2 = H, halo, etc.; R3 = H, OH-protecting group], useful as intermediates for cerebral function ameliorants, are prepd. from dihydrobenzothienophene II [R1 = as defined above]; II is prepd., e.g., by reaction of phenylloxoacetic acid

L7 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
derivs. III [X = halo; R1, R2 = as given above] with 2-mercaptoacetic  
acid, followed by 3 steps: redn., cyclization, and redn.  
IT 214355-69-8P 214355-78-9P  
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
(Preparation)  
(process for producing benzothiophenylhydroxyacetic acid derivs.

as pharmaceutical intermediates)  
RN 214355-69-8 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[2-(diethylamino)ethoxy]methyl]-6-  
fluoro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 214355-78-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[2-(diethylamino)ethoxy]methyl]-6-  
fluoro-, (+)-, 4-methylbenzenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 214355-69-8  
CMF C16 H22 F N O2 S

Rotation (+).




CM 2

CRN 104-15-4  
CMF C7 H8 O3 S

L7 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1998:414113 CAPLUS  
DOCUMENT NUMBER: 129:131175  
TITLE: The effects of T-588, a novel cognitive  
enhancer, on  
noradrenaline uptake and release in rat cerebral  
cortical slices  
AUTHOR(S): Maekawa, Mutsuko; Murayama, Toshihiko; Ono,  
Satoshi;  
CORPORATE SOURCE: Narita, Hirokazu; Nomura, Yasuyuki  
Pharmaceutical Department of Pharmacology, Faculty of  
Sciences, Hokkaido University, Sapporo, 060-0812,  
Japan  
SOURCE: Japanese Journal of Pharmacology (1998), 77(2),  
155-160  
CODEN: JJPAAZ; ISSN: 0021-5198  
PUBLISHER: Japanese Pharmacological Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB We investigated the effects of T-588 on noradrenaline (NA) uptake and  
release in rat cerebral cortical slices in comparison to the effects  
of desipramine, a blocker of the NA carrier on the cell plasma membrane.  
Both T-588 and desipramine caused dose-dependent inhibition of [3H]NA  
uptake by the slices. T-588 at 3 mM stimulated the [3H]NA release  
from the prelabeled slices even in the presence of 10 .mu.M desipramine,  
which inhibited the NA uptake completely. Tyramine, which accelerates NA  
carrier-mediated release, also stimulated the [3H]NA release and the  
tyramine-stimulated release was inhibited by desipramine. Thus, the  
T-588-stimulated NA release was not mediated by the inhibition of  
reuptake or reverse transport mediated by NA carriers. Reserpine, which  
interacts with the intracellular vesicular transport system, increased the  
[3H]NA efflux from slices. The high K+/not T-588-stimulated [3H]NA release  
was shifted upward by reserpine. T-588 may evoke the NA release by a  
mechanism similar to that of reserpine. T-588 may act as a cognitive  
enhancer via neurotransmitter release in the brain.  
IT 142935-03-3, t-588  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); BIOL (Biological study)  
(T-588 cognitive enhancer effects on noradrenaline uptake and  
release in rat brain cortical slices)  
RN 142935-03-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[2-(diethylamino)ethoxy]methyl]-,  
hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L7 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L7 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1998:251152 CAPLUS  
 DOCUMENT NUMBER: 128:321926  
 TITLE: Preparation of aspartate ester inhibitors of interleukin-1.beta. converting enzyme  
 INVENTOR(S): Albrecht, Hans P.; Allen, Hamish John; Brady, Kenneth  
 Lodge: Dale; Caprathe, Bradley William; Gilmore, John  
 Kostlan, Harter, William Glen; Hays, Sheryl Jeanne;  
 Kimberly, Catherine Rose; Lunney, Elizabeth Ann; Para, Suzanne; et al.  
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Albrecht, Hans P.; Allen,  
 Bradley, Hamish John; Brady, Kenneth Dale; Caprathe, William; Gilmore, John Lodge; Harter, William  
 Glen; Hays, Sheryl Jeanne; Kostlan, Catherine Rose  
 SOURCE: PCT Int. Appl., 179 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9816502	A1	19980423	WO 1997-US18514	19971009
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, HL, MR, NE, SN, TD, TG				
AU 9749023	A1	19980511	AU 1997-49023	19971009
AU 738341	B2	20010913		
EP 932598	A1	19990804	EP 1997-911715	19971009
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9712530	A	19991019	BR 1997-12530	19971009
JP 2001506974	T2	20010529	JP 1998-518519	19971009
NO 9901677	A	19990609	NO 1999-1677	19990409
KR 2000049048	A	20000725	KR 1999-703117	19990410
US 1996-28322P P 19961011				
WO 1997-US18514 W 19971009				
PRIORITY APPLN. INFO.: MARPAT 128:321926				
OTHER SOURCE(S): GI				

L7 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




AB The present invention relates to compds. I [R1 = carboxy, acyl, amino acid residue, etc.; R2 = (CR2)n-X-R3; each R = independently H, C1-6 alkyl, OH; R3 = (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl, cycloalkyl, etc; X = bond, O, S; n = 0-3; and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof] as inhibitors of interleukin-1.beta. converting enzyme (ICE). This invention also relates to a method of treatment of stroke, inflammatory diseases, reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable compn. that contains a compd. that is an inhibitor of interleukin-1.beta. converting enzyme. Thus, substitution of Z-Asp(OCMe3)-CH2Br (Z = PhCH2O2C) with 1-naphthylacetic acid, followed by acidic deprotection, gave desired aspartate ester deriv. II. II inhibited ICE with Ki = 0.460 .mu.M and IC50 = 3.100 .mu.M, and inhibited Ich-2 (caspase-4) with IC50 = 3.60 .mu.M, as detd. using in vitro assays. Related prepd. compds. I (196 examples) were also tested for ICE inhibition (Ki values of 0.00008 to 76 .mu.M and IC50 values of 0.0013 to 32 .mu.M), and Ich-2 inhibition (IC50 = 0.021 to 76 .mu.M).


IT 206863-09-4P 206863-10-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) [prepn. of aspartate ester inhibitors of interleukin-1.beta. converting enzyme]

RN 206863-09-4 CAPLUS  
 CN Benzo[b]thiophene-7-acetic acid, 4-carboxy-2-oxo-3-[(phenylmethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 206863-10-7 CAPLUS  
 CN Benzo[b]thiophene-4-acetic acid, 4-carboxy-2-oxo-3-[(phenylmethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1997:717804 CAPLUS  
 DOCUMENT NUMBER: 127:362624  
 TITLE: Patch containing 1,2-ethanediol derivatives or salts thereof  
 INVENTOR(S): Yamakawa, Tetsumi; Takakura, Keiko; Kubo, Yoshiko; Shinada, Yoko; Kodani, Masahiro; Tai, Masaru  
 PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan; Yamakawa, Tetsumi; Takakura, Keiko; Kubo, Yoshiko; Shinada, Yoko; Kodani, Masahiro; Tai, Masaru  
 SOURCE: PCT Int. Appl., 19 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9739740	A1	19971030	WO 1997-JP1363	19970421
W: AU, CA, CZ, HU, JP, KR, NZ, PL, RO, SK, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9725767	A1	19971112	AU 1997-25767	19970421
ZA 9703394	A	19971120	ZA 1997-3394	19970421
PRIORITY APPLN. INFO.: JP 1996-124041 A 19960422				
WO 1997-JP1363 W 19970421				
OTHER SOURCE(S): MARPAT 127:362624				
GI				




AB The invention relates to a patch comprising a substrate and, formed thereon, a plaster layer contg. the following components (a) to (d) exhibits higher drug absorption than that attained by oral administration, and is excellent in the persistence of blood drug level: (a) a 1,2-ethanediol deriv. of general formula (I) [R1 = H, halo or alkyl; R2-3 = alkyl] or a salt thereof; (b) urea; (c) polyethylene glycol; and (d) a film-forming nitrogenous polymer such as Eudragit E100 and Eudragit RS30D.

IT I are e.g. T-588 and 2-[2-(N,N-Diethylamino)ethoxy]-1-[6-fluorobenzo[b]thiophen-5-yl]ethanol.  
 142935-03-3, T-588 198412-24-7  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


L7 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 (transdermal patch contg. 1,2-ethanediol derivs. or salts thereof)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 198412-24-7 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
 fluoro- (9CI) (CA INDEX NAME)




L7 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl


RN 179616-62-7 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
 fluoro-, hydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 179616-76-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
 methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1997:576682 CAPLUS  
 DOCUMENT NUMBER: 127:210384  
 TITLE: Cerebral function ameliorant containing  
 1,2-ethanediol

INVENTOR(S): derivatives or salts thereof  
 Ono, Satoshi; Maekawa, Mutsuko; Hirata, Kazunari;  
 Narita, Hirokazu  
 PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan; Ono, Satoshi;  
 Maekawa, Mutsuko; Hirata, Kazunari; Narita,  
 Hirokazu  
 SOURCE: PCT Int. Appl., 14 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730703	A1	19970828	WO 1997-JP408	19970217
W: AU, CA, CZ, HU, JP, KR, NZ, PL, RO, SK, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
PT, SE	AU	9716725	AU 1997-16725	19970217
PRIORITY APPLN. INFO.:	JP	1996-56890	19960220	19970217
OTHER SOURCE(S): MARPAT 127:210384				

AB 1,2-Ethanediol derivs. and salts thereof, have the effects of ameliorating cerebral functions, such as antihypoxic and antiamnetic effects, and are thus useful as remedies for cerebrovascular dementia, senile dementia, Alzheimer's disease, sequelae of ischemic encephalopathy, and cerebral stroke. Antihypoxic and antiamnetic effects of (R)-2-[2-(N,N-

diethylamino)ethoxy]-1-(6-fluorobenzo[b]thiophen-5-yl)ethanol.cntdot.HCl (I) were tested with mice. Formulations contg. I for capsules and tablets

are also provided.

IT 179616-50-3 179616-62-7 179616-76-3

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES

(Uses)


(benzothiophenylethanol derivs. as cerebral function ameliorants)

RN 179616-50-3 CAPLUS

CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
 fluoro-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1997:437178 CAPLUS  
 DOCUMENT NUMBER: 127:116909  
 TITLE: T-588. Cognition enhancer  
 AUTHOR(S): Martel, A. M.; Prous, J.; Castaner-Prous, J.  
 CORPORATE SOURCE: Prous Science Publishers, Barcelona, 08080, Spain  
 SOURCE: Drugs of the Future (1997), 22(4), 386-390  
 CODEN: DRFUD4; ISSN: 0377-8282  
 PUBLISHER: Prous  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review with 28 refs. on the synthesis and pharmacol. actions of T-588.  
 IT 142935-03-3P, T 588  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (T-588: cognition enhancer)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

L7 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1997:424007 CAPLUS  
 DOCUMENT NUMBER: 127:130661  
 TITLE: Effects of  
 R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride  
 (T-588), a novel cognitive enhancer, on noradrenaline release in rat cerebral cortical slices  
 AUTHOR(S): Miyazaki, Hiroyuki; Murayama, Toshihiko; Ono, Satoshi;  
 CORPORATE SOURCE: Narita, Hirokazu; Nomura, Yasuyuki  
 PHARMACEUTICAL: DEPARTMENT OF PHARMACOLOGY, FACULTY OF SCIENCES, HOKKAIDO UNIVERSITY, SAPPORO, 060, Japan  
 SOURCE: Biochemical Pharmacology (1997), 53(9), 1263-1269  
 PUBLISHER: CODEN: BCPA6; ISSN: 0006-2952  
 DOCUMENT TYPE: Elsevier  
 LANGUAGE: English  
 AB The authors investigated the effects of R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588), a novel cognitive enhancer, on noradrenaline (NA) release from rat cerebral cortical slices in vitro. Addn. of T-588 in an assay mixt. stimulated [3H]NA release from prelabeled slices in the presence or absence of extracellular CaCl2, and in the presence of the Ca2+/calmodulin antagonists N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide and trifluoperazine. T-588 stimulated NA release with a time lag of about 1 min, and the high level of release was maintained for at least 10 min, whereas maximal KCl-evoked NA release was obsd. within 1 min after the addn. of KCl, and the effect declined subsequently. The effect of T-588 was reversible (pretreatment with T-588 showed no effect on NA release after two washes by centrifugation). The authors also compared the effects of T-588 and N-ethylmaleimide (NEM), a sulfhydryl alkylating agent known to stimulate neurotransmitter release in several types of cells. The addn. of NEM stimulated NA release irreversibly from the slices in a Ca2+-independent manner, and the effect of NEM, but not that of T-588, was inhibited by the simultaneous addn. of dithiothreitol, a sulfhydryl reducing agent. The addn. of T-588, which stimulated NA release by itself, inhibited the NA release by 0.6 mM NEM, although the effect of T-588 was additive in the presence of 0.2 mM NEM. These findings suggest


L7 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 that T-588 stimulates NA release from rat cerebral cortical slices in a Ca2+-and calmodulin-independent manner, possibly via an NEM-sensitive factor(s), although the mechanism of the effects of T-588 seems to be different from that of NEM.  
 IT 142935-03-3, T-588  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (effects of cognitive enhancer (benzo[b]thiophenyl)[(diethylamino)ethoxy]ethanol hydrochloride (T-588) on noradrenaline release in rat cerebral cortical slices)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




● HCl

L7 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1996:622600 CAPLUS  
 DOCUMENT NUMBER: 125:264873  
 TITLE: Quantitative determination of T-588 and its metabolites in human serum by LC/ESI/MS  
 AUTHOR(S): Yamamoto, Yoshitaka; Sakai, Hiroshi; Tanaka, Hayakawa, Hiroyoshi; Mae, Michiko; Segawa, Kyoko;  
 CORPORATE SOURCE: Nakashima, Yoshifumi  
 Res. Laboratories, Toyama Chemical Co., Ltd., Japan  
 SOURCE: Nippon Iyo Masu Supekutoru Gakkai Koenshu  
 (1996), 21, 223-226  
 PUBLISHER: CODEN: NIMKEN; ISSN: 0916-085X  
 DOCUMENT TYPE: Nippon Iyo Masu Supekutoru Gakkai  
 LANGUAGE: Japanese  
 AB T-588 is a benzothiophene deriv., which is expected the usefulness in clin. treatment of cerebrovascular disorders and Alzheimer's disease. A simple and precise LC/ESI/MS method was developed for the simultaneous detn. of T-588 and its metabolites in human serum. In the serum, the samples spiked with T-588 and its metabolites, the calibration curves showed good linearity in the range of 2(5)-100 ng/mL. The lower detection limits were 50-100 pg. It was recognized that present assay method has sufficient precision, rapidity and simplicity in execution.  
 IT 142935-03-3, T-588 142935-03-3D, T-588, metabolites  
 RL: ANT (Analyte); ANST (Analytical study)  
 (quant. detn. of T-588 and its metabolites in human serum by LC/ESI/MS)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L7 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



● HCl



● HCl


RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-,



L7 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1996:476633 CAPLUS  
 DOCUMENT NUMBER: 125:142540  
 TITLE: Preparation of potentiator for nerve growth factor  
 INVENTOR(S): activity containing 1,2-ethanediol derivatives  
 Ono, Satoshi; Maekawa, Mutsuko; Hirata, Kazunari;  
 Narita, Hirokazu  
 PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: FIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9612717	A1	19960502	WO 1995-JP2162	19951020
W: AU, CA, CZ, HU, JP, KR, NZ, PL, RO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE				
JP 08268883	A2	19961015	JP 1994-284273	19941025
CA 2202032	AA	19960502	CA 1995-2202032	19951020
AU 9537097	A1	19960515	AU 1995-37097	19951020
AU 700561	E2	19990107		
EP 790246	A1	19970820	EP 1995-934859	19951020
EP 790246	B1	20020116		
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
HU 77361	A2	19980330	HU 1997-1903	19951020
EP 1020427	A1	20000719	EP 2000-100580	19951020
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 3218247	B2	20011015	JP 1996-513778	19951020
JP 2002037730	A2	20020206	JP 2001-164799	19951020
EP 1223169	A1	20020717	EP 2002-4782	19951020
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
ES 2171559	T3	20020916	ES 1995-934859	19951020
ZA 9508991	A	19970424	ZA 1995-8991	19951024
US 5807887	A	19980915	US 1997-809407	19970423
US 5922721	A	19990713	US 1997-1656	19971231
US 5932620	A	19990803	US 1997-1651	19971231
US 5968935	A	19991019	US 1997-1650	19971231
US 6034119	A	20000307	US 1999-252199	19990218
US 6103754	A	20000815	US 1999-264713	19990309
PRIORITY APPLN. INFO.:				
			JP 1994-284272	A 19941025
			JP 1994-284273	A 19941025
			EP 1995-934859	A3 19951020
			EP 2000-100580	A3 19951020
			JP 1996-513778	A3 19951020
			WO 1995-JP2162	W 19951020
			US 1997-1656	A3 19971231
OTHER SOURCE(S): MARPAT 125:142540				
GI				

L7 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl


RN 131964-48-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(dimethylamino)ethoxy]methyl]-  
 2,3-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142935-01-1 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(dimethylamino)ethoxy]methyl]-  
 hydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 142935-02-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(diethylamino)ethoxy]methyl]-  
 hydrochloride, (S)- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



II

AB The compd. and its salts [I: R1 = (substituted) Ph, naphthyl, indanyl, indenyl, tetrahydronaphthyl or heterocyclic group; R2 = H, alkyl or a hydroxyl-protecting group; R3 = H or lower alkyl; R4, R5 = H, lower alkyl; R6 = (substituted) NH2 or a N heterocyclic group, or ammonior and n = 0-6] having an excellent nerve growth factor potentiating effect and are useful as a remedy for various diseases caused by central or peripheral nervous system degeneration, such as senile dementia of Alzheimer type, Huntington's chorea, various types of neuropathy and Riley-Day syndrome, traumatic neurosis and amyotrophic lateral sclerosis (ALS), are prepd. and formulated. Thus, 10-5 M of II in vitro gave 136% nerve growth potentiation vs. control.


IT 131964-30-2P 131964-48-2P 142935-01-1P  
 142935-02-2P 142935-03-3P 179616-48-9P  
 179616-49-0P 179616-50-3P 179616-51-4P  
 179616-57-0P 179616-58-1P 179616-59-2P  
 179616-60-5P 179616-63-8P 179616-64-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (potentiator for nerve growth factor activity contg. benzofuran or benzothienyl 1,2-ethanediol derivs. for treatment of central or peripheral nervous system degeneration)

RN 131964-30-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(dimethylamino)ethoxy]methyl]-  
 hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry.



● HCl


RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(diethylamino)ethoxy]methyl]-  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179616-48-9 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[2-(diethylamino)ethoxy]methyl]-  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-49-0 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-[(3,4-dimethoxyphenyl)ethyl]ethylamino]ethoxy]methyl]-, hydrochloride (9CI)




● HCl

RN 179616-50-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
fluoro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-51-4 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-4-  
fluoro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-57-0 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-4-  
methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-63-8 CAPLUS  
CN Benzo[b]thiophene-5-methanol, 4-bromo-.alpha.-[[2-  
(diethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-64-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol, 6-bromo-.alpha.-[[2-  
(diethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 179616-61-6P 179616-62-7P 179616-70-7P  
179616-71-8P 179616-72-9P 179616-73-0P  
179616-75-2P 179616-76-3P 179616-77-4P  
179616-78-5P 179616-79-6P 179616-80-9P  
179616-81-0P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL  
(Biological study); PREP (Preparation); USES (Uses)  
(potentiator for nerve growth factor activity contg. benzofuran or




● HCl

RN 179616-58-1 CAPLUS  
CN Benzo[b]thiophene-5-methanol, 4-chloro-.alpha.-[[2-  
(diethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179616-59-2 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-3-  
phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-60-5 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
methoxy-, hydrochloride (9CI) (CA INDEX NAME)

RN 179616-61-6 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
fluoro-, hydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 179616-62-7 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
fluoro-, hydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179616-70-7 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-7-  
fluoro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-71-8 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-2-  
fluoro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-72-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-3-  
fluoro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-73-0 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-2-  
methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-77-4 CAPLUS  
CN Benzo[b]thiophene-5-methanol, 4-chloro-.alpha.-[[2-  
(diethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-78-5 CAPLUS  
CN Benzo[b]thiophene-5-methanol, 6-chloro-.alpha.-[[2-  
(diethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179616-79-6 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-2-  
phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-75-2 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-3-  
methyl-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CFM 179616-74-1  
CMF C17 H25 N O2 S




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 179616-76-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179616-80-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol, 4-bromo-.alpha.-[[2-  
(diethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179616-81-0 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-6-  
fluoro-, hydrochloride (9CI) (CA INDEX NAME)



L7 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1996:25037 CAPLUS  
 DOCUMENT NUMBER: 124:135478  
 TITLE: A new cognition-enhancing agent, (R)-(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride.

Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions

AUTHOR(S): Ono, Satoshi; Yamafuji, Tetsuo; Chaki, Hisaaki; Todo, Yozo; Maekawa, Mutsuko; Kitamura, Kazunori; Kimura, Tatsuo; Nakada, Yasushi; Mozumi, Kuniko; Narita, Hirokazu

CORPORATE SOURCE: Res. Lab., Toyama Chemical Co., Ltd., Toyama, 930, Japan

SOURCE: Biological & Pharmaceutical Bulletin (1995), 18(12), 1779-83

PUBLISHER: CODEN: EPBLEO; ISSN: 0918-6158  
 DOCUMENT TYPE: Pharmaceutical Society of Japan  
 LANGUAGE: English


AB The title compd. (T-588) has been evaluated for its ameliorating effect on memory impairment generated by cerebral embolization and by a basal forebrain (BF) lesion in male Wistar rats. The memory and learning deficits induced by injection of carbon-microspheres into the internal carotid artery were significantly improved by T-588 at oral dose of 3-10 mg/kg, as detd. by an active avoidance response assay, whereas the drugs (tacrine, idobenone and indoxazine) proved almost inactive in the same assay procedure. As far as the embolization was concerned, a significant decrease in cerebral acetylcholine and monoamines was obsd. The effect on the memory impairment caused by an electrolytic lesion of the BF was assessed by a passive avoidance task. T-588 exhibited a bell-shaped dose-response curve and was most active at 1 mg/kg (oral dose), while tacrine showed equal activity at 10 mg/kg.

IT 142935-02-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)

(a new cognition-enhancing agent, (R)-(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride. Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions)


L7 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 (a new cognition-enhancing agent, (R)-(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride. Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions)

RN 131965-06-5 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 173289-10-6 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)



L7 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 RN 142935-02-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 142935-03-3P, T-588  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(a new cognition-enhancing agent, (R)-(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride. Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions)

RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(diethylamino)ethoxy]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 131965-06-5 173289-10-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

L7 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1995:902191 CAPLUS  
 DOCUMENT NUMBER: 124:21033  
 TITLE: Studies on cognitive enhancing agents. III. Antiamnesic and antihypoxic activities of a series of 1-bicycloaryl-2-(omega-aminalkoxy)ethanols

AUTHOR(S): Ono, Satoshi; Yamafuji, Tetsuo; Chaki, Hisaaki; Morita, Hajime; Todo, Yozo; Okada, Naomi; Maekawa, Mutsuko; Kitamura, Kazunori; Tai, Masaru; Narita, Hirokazu

CORPORATE SOURCE: Res. Lab., Toyama Chem. Co., Ltd., Toyama, 930, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1995), 43(9), 1492-6

PUBLISHER: CODEN: CPBTAL; ISSN: 0009-2363  
 DOCUMENT TYPE: Pharmaceutical Society of Japan  
 LANGUAGE: English

AB 2-(2-Aminoethoxy)-1-hydroxyethyl derivs. of bicyclic arenes (naphthalene, thianaphthene, benzofuran, and indole) were prepd. and screened for antiamnesic (AA) and antihypoxic (AH) activities which were evaluated by measuring the reversing potency in electroconvulsion-induced amnesia and the protective effect against hypoxia, resp., in mice.


1-(Benzo[b]thiophen-5-yl)-2-(2-diethylaminoethoxy)ethanol (I), showed the best AA and AH activity profile, being superior to the prototype compd. 2-(2-dimethylaminoethoxy)-1-phenylethanol. Elongation of the ethylene linkage in the side chain of I to 3- and 4-carbon moieties brought about a significant decrease in AH activity. I was further investigated for its protective effects against CO2-induced memory impairment and for acute toxicity in mice. It is ten-fold more potent than tacrine in the amnesia-reversal assay and is considerably less toxic than tacrine.

IT 131964-30-2P 131964-36-6P 131964-48-2P  
 131964-49-3P 131964-50-6P 131965-06-5P  
 142934-94-9P 142934-97-2P 142934-98-3P  
 171436-01-4P 171436-02-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. and antiamnesic and antihypoxic activities of bicycloaryl(aminalkoxy)ethanols)

RN 131964-30-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[2-(dimethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131964-36-8 CAPLUS  
CN Benzo[b]thiophene-7-methanol,  
.alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131964-48-2 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
2,3-dihydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131964-49-3 CAPLUS  
CN Benzo[b]thiophene-4-methanol,  
.alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




RN 142934-97-2 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-bis(1-methylethyl)amino]ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142934-98-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[4-(diethylamino)butoxy]methyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 171436-01-4 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[(2-aminoethoxy)methyl]-,  
(2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CN 1

CRN 131964-72-2  
CMF C12 H15 N O2 S




● HCl

RN 131964-50-6 CAPLUS  
CN Benzo[b]thiophene-6-methanol,  
.alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131965-06-5 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 142934-94-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[3-(diethylamino)propoxy]methyl]-,  
(9CI) (CA INDEX NAME)




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



RN 171436-02-5 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(ethylamino)ethoxy]methyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




● HCl

L7 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1994:106751 CAPLUS  
 DOCUMENT NUMBER: 120:106751  
 TITLE: Process for the preparation of chiral benzo[b]thiophen-5-yl derivatives  
 INVENTOR(S): Nakano, Joji; Taya, Nobuhisa; Chaki, Hisaaki; Yamafuji, Tetsuo; Momono, Kaishu  
 PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 20 pp.  
 CODEN: EFXKDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 565965	A2	19931020	EP 1993-105441	19930401
EP 565965	A3	19940302		
EP 565965	B1	19961113		
R: AT, CH, DE, DK, GB, LI, NL, SE				
JP 06009615	A2	19940118	JP 1993-90934	19930325
JP 2873898	B2	19990324		
CA 2093048	AA	19931014	CA 1993-2093048	19930331
CA 2093048	C	19961008		
AT 145204	E	19961115	AT 1993-105441	19930401
AU 643634	B1	19931118	AU 1993-35659	19930402
ZA 9302493	A	19931112	ZA 1993-2493	19930407
ES 2060545	A1	19941116	ES 1993-733	19930407
ES 2060545	B1	19971201		
FR 2689890	A1	19931015	FR 1993-4226	19930409
FR 2689890	B1	19950106		
HU 64319	A2	19931128	HU 1993-1052	19930409
HU 213631	B	19970828		
HU 214106	B	19971229	HU 1997-1324	19930409
CZ 290421	B6	20020717	CZ 1993-610	19930409
RO 115445	B1	20000228	RO 1993-505	19930412
BE 1006403	A3	19940816	BE 1993-363	19930413
PL 171832	B1	19970630	PL 1993-315676	19930413
PL 171831	B1	19970630	PL 1993-315677	19930413
PL 172191	B1	19970829	PL 1993-298494	19930413
US 5380878	A	19950110	US 1994-217960	19940329
CZ 289428	B6	20020116	CZ 1994-1926	19940809
CZ 290864	B6	20021113	CZ 1994-1925	19940809
PRIORITY APPLN. INFO.:				
			JP 1992-119740	A 19920413
			JP 1993-90934	A 19930325
			US 1993-42510	B1 19930405
			CZ 1993-610	A3 19930409
			HU 1993-1052	A 19930409
OTHER SOURCE(S):				
GI			MARPAT 120:106751	

L7 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB The title compds. I and II (R2 = H, OH-protecting group; R4, R5 = lower alkyl) are prepd. by inoculating into a supersatd. soln. of benzothiophene III R or S enantiomers of III, collecting the enantiomerically pure ppt., subjecting the ppt. to alcoholysis or hydrolysis, introducing a hydroxyl- and a carboxyl-protecting group, reducing the intermediates to produce optically active methylol derivs., condensing the methylol derivs. with XCH2CH2NHR4R5 (X = removable group), and removing the hydroxyl-protecting group. Thus, in this manner, (-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (m.p. 120-121.degree.) was prepd. in 90% yield.  
 IT 142935-03-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prep. of)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol.  
 .alpha.-[2-(diethylamino)ethoxymethyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

L7 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


L7 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1993:485836 CAPLUS  
 DOCUMENT NUMBER: 119:485836  
 TITLE: Protective effect of R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588), a novel cerebral activator, against experimental cerebral anoxia  
 AUTHOR(S): Ono, Satoshi; Kitamura, Kazunori; Maekawa, Mutsuko  
 Yamafujii, Hirata, Kazunari; Ano, Motoko; Ukai, Wataru  
 CORPORATE SOURCE: Tetsuo; Narita, Hirokazu  
 Shimookui, Res. Lab., Toyama Chem. Co., Ltd., 2-4-1, 930, Japan  
 SOURCE: Japanese Journal of Pharmacology (1993), 62(1), 81-6  
 DOCUMENT TYPE: CODEN: JJPAAZ; ISSN: 0021-5198  
 LANGUAGE: Journal  
 GI English



AB Effects of R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588, I) on normobaric hypoxia, histotoxic anoxia by KCN and complete ischemia by decapitation were investigated in mice. T-588 (30-100 mg/kg, p.o.) showed a significant and dose-dependent prolongation of the survival time in all of the models studied. Bifemelane (100-300 mg/kg, p.o.) was also protective against all the models. Tacrine was protective against hypoxia but had no effect on anoxia and ischemia. Imipramine was protective against anoxia, but shortened the survival time of hypoxic mice. It had no effect on ischemia. The anti-hypoxic effect of T-588 was completely inhibited by pretreatment with scopolamine (1 mg/kg, i.p.), while the anti-anoxic effect was partially inhibited. Its effect on the ischemia was not affected by scopolamine. Hypoxia decreased the cerebral contents of ATP, phosphocreatine and glucose and increased the contents of lactate in mice. T-588 had no effect on these changes. Bifemelane prolonged pentobarbital-induced sleeping time in mice with the doses inducing

L7 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 anti-anoxic action, but T-588 did not. These results suggest that  
 the activation of the CNS cholinergic system is involved as one of the  
 mechanisms for the anti-anoxic action of T-588.  
 IT 142935-03-3, T 588  
 RL: BIOL (Biological study)  
 (cognition enhancement by, CNS cholinergic system activation in)  
 RN 142935-03-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L7 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1992:490114 CAPLUS  
 DOCUMENT NUMBER: 117:90114  
 TITLE: Preparation and formulation of  
 heterocyclyethanediol  
 INVENTOR(S): derivatives and salts as brain function improvers  
 Maekawa, Ono, Satoru; Santo, Tetsuo; Chaki, Hisaaki;  
 PATENT ASSIGNEE(S): Mutsuko; Todo, Yozor; Narita, Hirokazu  
 SOURCE: Toyama Kagaku Kogyo K. K., Japan  
 Jpn. Kokai Tokkyo Koho, 26 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04095070	A2	19920327	JP 1990-211348	19900809
JP 3044055	B2	20000522		

PRIORITY APPLN. INFO.: MARPAT 117:90114  
 OTHER SOURCE(S): GI




AB R1CH(OR2)CHR3O(CR4R5)nR6 [I; R1 = (substituted) heterocyclyl; R2 = H,  
 alkyl, protecting group; R3 = H, alkyl; R4, R5 = H, alkyl; R6 = NH2,  
 N-heterocyclyl, ammonio; n = 0-6], useful as brain function improvers  
 in treating amnesia, senility, Alzheimer's disease, etc., are prepd.  
 Me3COX was added to 31 mL Me2NCH2CH2OH with heating at 80.degree., the mixt.  
 was treated with a soln. of 5.2 g 2-(benzo[b]thiophen-5-yl)oxirane in DMF  
 at 80-85.degree., the mixt. was worked up and treated with 6N HCl to  
 give 3.3 g II.HCl, which showed 2.21-fold increase in survival rate as  
 antihypoxia agent at 25 mg/kg orally in mice and moderate effectiveness as  
 anti-amnesia agent at 10 mg/kg orally in mice. Also prepd. and tested were 119  
 addnl.  
 1. Tablet and capsule formulation were given.  
 IT 131964-36-8P 131964-48-2P 131964-49-3P  
 131964-50-6P 131964-52-8P 131964-63-1P  
 131964-64-2P 131964-72-2P 131964-73-3P  
 131964-76-6P 131965-00-9P 131965-01-0P  
 131965-02-1P 131965-06-5P 131965-14-5P

L7 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 131965-15-6P 131965-16-7P 131965-17-8P  
 131965-19-0P 131965-20-3P 131965-46-3P  
 132007-81-9P 132007-82-0P 142934-80-3P  
 142934-83-6P 142934-91-6P 142934-93-8P  
 142934-94-9P 142934-97-2P 142934-98-3P  
 142934-99-4P 142935-00-0P 142935-01-1P  
 142935-02-2P 142935-03-3P 142935-06-6P  
 142935-07-7P 142935-08-8P 142935-09-9P  
 142935-12-4P 142935-13-5P 142935-14-6P  
 142935-15-7P 142950-70-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as brain function improver)  
 RN 131964-36-8 CAPLUS  
 CN Benzo[b]thiophene-7-methanol,  
 .alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131964-48-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
 2,3-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131964-49-3 CAPLUS  
 CN Benzo[b]thiophene-4-methanol,  
 .alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 131964-50-6 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131964-52-8 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[4-(dimethylamino)butoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131964-63-1 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(methylanino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131964-64-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(cyclopropylamino)ethoxy]methyl]-  
 , hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131964-72-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[(2-aminoethoxy)methyl]- (9CI)  
 (CA INDEX NAME)




RN 131964-73-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[(2-aminoethoxy)methyl]-,  
 (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 131964-72-2  
 CMF C12 H15 N O2 S




RN 131965-01-0 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[3-(cyclopropylamino)propoxy]methyl]-  
 ], hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131965-02-1 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[3-[(1-methylethyl)amino]propoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131965-06-5 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)



CM 2

CRN 110-17-8  
 CMF C4 H4 O4


Double bond geometry as shown.



RN 131964-76-6 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(2-pyrimidinylamino)ethoxy]methyl]-,  
 (2Z)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 131964-75-5  
 CMF C16 H17 N3 O2 S




CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 131965-00-9 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[3-(methylamino)propoxy]methyl]-




● HCl

RN 131965-14-5 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[3-(dimethylamino)propoxy]methyl]-  
 (9CI) (CA INDEX NAME)




RN 131965-15-6 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[3-(methylamino)propoxy]methyl]-  
 (9CI) (CA INDEX NAME)




RN 131965-16-7 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[2-(methylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 131965-17-8 CAPLUS  
CN Benzo[b]thiophene-6-methanol,  
.alpha.-[[2-(cyclopropylamino)ethoxy]methyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131965-19-0 CAPLUS  
CN Ethanaminium,  
2-(2-benzo[b]thien-5-yl-2-hydroxyethoxy)-N,N,N-trimethyl-,  
1,5-naphthalenedisulfonate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 131965-19-9  
CMF C15 H22 N O2 S



CM 2

CRN 22713-47-9  
CMF C10 H6 O6 S2

RN 132007-82-0 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(tricyclo[3.3.1.1.3,7]dec-1-ylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 142934-80-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(dimethylamino)propoxy]methyl]-,  
(2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 131964-53-9  
CMF C15 H21 N O2 S




CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142934-83-6 CAPLUS  
CN 2-Pyridinecarboxamide,  
N-[2-(2-benzo[b]thien-5-yl-2-hydroxyethoxy)ethyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)




RN 131965-20-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
acetate (ester), hydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 131965-46-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
(9CI) (CA INDEX NAME)



RN 132007-81-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[3-(dimethylamino)propoxy]methyl]-,  
(9CI) (CA INDEX NAME)




● HCl

RN 142934-91-6 CAPLUS  
CN Benzo[b]thiophene-4-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
(2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 142934-90-5  
CMF C16 H23 N O2 S



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142934-93-8 CAPLUS  
CN Benzo[b]thiophene-6-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
(2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 142934-92-7  
CMF C16 H23 N O2 S




CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142934-94-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[3-(diethylamino)propoxy)methyl]-  
(9CI) (CA INDEX NAME)




RN 142934-97-2 CAPLUS  
CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-[bis(1-methylethyl)amino]ethoxy)methyl]-, hydrochloride {9CI} (CA INDEX NAME)



● HCl

RN 142934-98-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[4-(diethylamino)butoxy)methyl]-.


Absolute stereochemistry.



● HCl

RN 142935-02-2 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
hydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 142935-03-3 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[2-(diethylamino)ethoxy]methyl]-,  
hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



● HCl


RN 142934-99-4 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(diethylamino)ethoxy]methyl]-2,3-  
dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142935-00-0 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 142935-01-1 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[2-(dimethylamino)ethoxy]methyl]-.

RN 142935-06-6 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[3-(dimethylamino)propoxy)methyl]-,  
hydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 142935-07-7 CAPLUS  
CN Benzo[h]thiophene-5-methanol,  
.alpha.-[[3-(dimethylamino)propoxy)methyl]-,  
hydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 142935-08-8 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[3-(diethylamino)propoxy)methyl]-,  
(S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 142935-09-9 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[3-(diethylamino)propoxy]methyl]-,  
(R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142935-12-4 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[4-(dimethylamino)butoxy]methyl]-,  
hydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 142935-13-5 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[4-(dimethylamino)butoxy]methyl]-,  
hydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L7 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



CH 2


CRN 144-62-7  
CMF C2 H2 O4



L7 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 142935-14-6 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[4-(diethylamino)butoxy]methyl]-,  
hydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 142935-15-7 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[4-(diethylamino)butoxy]methyl]-,  
hydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 142950-70-7 CAPLUS  
CN Benzo[b]thiophene-5-methanol,  
.alpha.-[[2-(methyl(phenylmethyl)amino)ethoxy]methyl]-,  
ethanediolate (1:1) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 131964-67-5  
CMF C20 H23 N O2 S


L7 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:01222 CAPLUS  
DOCUMENT NUMBER: 11481222  
TITLE: Preparation of aromatic 1,2-ethanediol derivatives as  
INVENTOR(S): drugs  
Ono, Satoshi; Yamafuji, Tetsuo; Chaki, Hisaaki;  
Maekawa, Mutsuko; Todo, Yozo; Narita, Hirokazu  
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 163 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 383281	A1	19900822	EP 1990-102829	19900213
EP 383281	B1	19940817		
R: AT, CH, DE, DK, GB, LI, NL, SE				
JP 03047158	A2	19910228	JP 1990-24502	19900205
JP 2913196	B2	19990628		
JP 03197422	A2	19910828	JP 1990-24501	19900205
JP 2913195	B2	19990628		
JP 03232830	A2	19911016	JP 1990-24503	19900205
JP 2887492	B2	19990426		
CA 2009886	AA	19900814	CA 1990-2009886	19900213
CA 2009886	C	19971111		
AU 9049392	A1	19900823	AU 1990-49392	19900213
AU 633539	B2	19930204		
HU 58272	A2	19920228	HU 1990-780	19900213
DD 299960	A5	19920514	DD 1990-337803	19900213
ES 2027468	A6	19920601	ES 1990-428	19900213
CZ 278503	B6	19940216	CZ 1990-680	19900213
EP 587193	A1	19940316	EP 1993-115717	19900213
EP 587193	B1	19970102		
R: AT, CH, DE, DK, GB, LI, NL, SE				
EP 587194	A1	19940316	EP 1993-115719	19900213
EP 587194	B1	19970604		
R: AT, CH, DE, DK, GB, LI, NL, SE				
EP 589484	A1	19940330	EP 1993-115918	19900213
EP 589484	B1	19961016		
R: AT, CH, DE, DK, GB, LI, NL, SE				
SK 277973	B6	19950913	SK 1990-680	19900213
AT 144243	E	19961115	AT 1993-115918	19900213
AT 147065	E	19970115	AT 1993-115717	19900213
AT 154009	E	19970615	AT 1993-115719	19900213
HU 219345	B	20010328	HU 1980-90007	19900213
FR 2643079	A1	19900817	FR 1990-1750	19900214
FR 2643079	B1	19971003		
ZA 9001122	A	19901128	ZA 1990-1122	19900214
BE 1003168	A5	19911217	BE 1990-162	19900214
RO 108678	B1	19940729	RO 1990-144169	19900214
PL 166611	B1	19950630	PL 1990-283790	19900214
PL 166607	B1	19950630	PL 1990-300750	19900214
US 5280032	A	19940118	US 1992-940747	19920908

L7 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 US 5472984 A 19951205 US 1993-174793 19931229  
 US 5658904 A 19970819 US 1995-466830 19950606  
 US 5612381 A 19970318 US 1995-478810 19950607  
 US 5719150 A 19980217 US 1996-749143 19961114  
 US 5872117 A 19990216 US 1997-964323 19971104  
 PRIORITY APPLN. INFO.: JP 1989-32714 A 19890214  
 JP 1989-68958 A 19890320  
 JP 1989-106187 A 19890426  
 JP 1990-24501 A 19900205  
 JP 1990-24502 A 19900205  
 JP 1990-24503 A 19900205  
 US 1990-480114 B2 19900214  
 US 1990-566889 B1 19900814  
 US 1992-940747 A3 19920908  
 US 1993-174793 A3 19931229  
 US 1995-478810 A3 19950607  
 US 1996-749143 A3 19961114


OTHER SOURCE(S): MARPAT 114:81222  
 GI



● HCl  
 I


AB 1,2-Ethanediol derivs. R2OCHR1CHR3O(CR4R5)nR6 [R1 = (substituted) Ph, aryl, or heterocyclyl; R2 = H, C1-6 alkyl or OR2 = protected hydroxy; R3, R4, R5 = H, C1-6 alkyl; R6 = (substituted or cyclic) amino, N-contg. heterocyclyl; n = 0-6], useful as cerebral function-improving agents, were prepd. For example, reaction of Me2N(CH2)2OH with 2-(3-fluorophenyl)oxirane in the presence of tert-BuOK, followed by reaction with HCl(g), gave I. In a test against cycloheximide-induced amnesia, I at 3 mg/kg orally in mice gave a response latency of 101-150 s vs. 0-60 s for the control group. I also showed activity as an antihypoxic and an acetylcholinesterase inhibitor. Over 400 title compds. were prepd.  
 IT 131964-30-2P 131964-48-8P 131964-49-3P 131964-50-6P 131964-52-8P 131964-54-0P 131964-63-1P 131964-64-2P 131964-68-5P 131964-72-2P 131964-73-3P 131964-75-5P 131964-76-6P 131964-77-7P 131965-00-9P 131965-01-0P 131965-02-1P 131965-06-5P 131965-14-5P 131965-15-6P 131965-16-7P 131965-17-8P 131965-19-0P 131965-20-3P 131965-46-3P 131965-47-4P 131965-48-5P 131965-49-6P 132007-81-9P 132007-82-0P

L7 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of, as drug)  
 RN 131964-30-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(dimethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131964-36-8 CAPLUS  
 CN Benzo[b]thiophene-7-methanol, .alpha.-[[2-(dimethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131964-48-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(dimethylamino)ethoxy]methyl]-, 2,3-dihydro-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 131964-49-3 CAPLUS  
 CN Benzo[b]thiophene-4-methanol, .alpha.-[[2-(dimethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131964-50-6 CAPLUS  
 CN Benzo[b]thiophene-6-methanol, .alpha.-[[2-(dimethylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 131964-52-8 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[4-(dimethylamino)butoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 131964-54-0 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(dimethylamino)propoxy]methyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 131964-53-9  
 CMF C15 H21 N O2 S




CM 2

CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 131964-63-1 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(methylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 131964-64-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(cyclopropylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131964-68-6 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-[methyl(phenylmethyl)amino]ethoxy]methyl]-,  
 ethanedioate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 131964-67-5  
 CMF C20 H23 N O2 S



CM 2


CRN 144-62-7  
 CMF C2 H2 O4



RN 131964-76-6 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(2-pyrimidinylamino)ethoxy]methyl]-,  
 (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 131964-75-5  
 CMF C16 H17 N3 O2 S




CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 131964-77-7 CAPLUS  
 CN 3-Pyridinacarbonylcarboxamide,  
 N-[2-(2-benzo[b]thien-5-yl-2-hydroxyethoxy)ethyl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131965-00-9 CAPLUS




RN 131964-72-2 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[(2-aminoethoxy)methyl]-,  
 (CA INDEX NAME)



RN 131964-73-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[(2-aminoethoxy)methyl]-,  
 (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 131964-72-2  
 CMF C12 H15 N O2 S



CM 2


CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 131964-75-5 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(2-pyrimidinylamino)ethoxy]methyl]-,  
 (9CI) (CA INDEX NAME)

RN 131964-75-5 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(2-pyrimidinylamino)ethoxy]methyl]-,  
 (9CI) (CA INDEX NAME)




RN 131965-01-0 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[3-(cyclopropylamino)propoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131965-02-1 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[3-((1-methylethyl)amino)propoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131965-06-5 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(diethylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 131965-14-5 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[3-(dimethylamino)propoxy]methyl]-  
 (9CI) (CA INDEX NAME)



RN 131965-15-6 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[3-(methylamino)propoxy]methyl]-  
 (9CI) (CA INDEX NAME)




RN 131965-16-7 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[2-(methylamino)ethoxy]methyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 131965-17-8 CAPLUS  
 CN Benzo[b]thiophene-6-methanol,  
 .alpha.-[[2-(cyclopropylamino)ethoxy]methyl]-  
 , hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131965-19-0 CAPLUS  
 CN Ethanaminium,  
 2-(2-benzo[b]thien-5-yl-2-hydroxyethoxy)-N,N,N-trimethyl-  
 1,5-naphthalenedisulfonate (2:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 131965-18-9  
 CMF C15 H22 N O2 S




CM 2

CRN 22713-47-9  
 CMF C10 H6 O6 S2




RN 131965-20-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(dimethylamino)ethoxy]methyl]-,  
 acetate (ester), hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 131965-46-3 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(dimethylamino)ethoxy]methyl]-  
 (9CI) (CA INDEX NAME)




RN 131965-47-4 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-(methylamino)ethoxy]methyl]-  
 (9CI) (CA INDEX NAME)




RN 131965-48-5 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[2-[(triphenylmethyl)amino]ethoxy]methyl]-  
 ethyl]- (9CI) (CA INDEX NAME)




RN 131965-49-6 CAPLUS  
 CN 3-Pyridinecarboxamide,  
 N-[2-(2-benzo[b]thien-5-yl-2-hydroxyethoxy)ethyl]-  
 (9CI) (CA INDEX NAME)



RN 132007-81-9 CAPLUS  
 CN Benzo[b]thiophene-5-methanol,  
 .alpha.-[[3-(dimethylamino)propoxy]methyl]-  
 (9CI) (CA INDEX NAME)



RN 132007-82-0 CAPLUS  
 CN Benzo[b]thiophene-5-methanol, .alpha.-[[2-(tricyclo[3.3.1.1.3,7]dec-1-ylamino)ethoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	168.25	481.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-24.09	-24.09

STN INTERNATIONAL LOGOFF AT 13:14:25 ON 01 APR 2003